<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002988" GROUP_ID="AIRWAYS" ID="172200101409072182" MERGED_FROM="" MODIFIED="2012-02-10 12:27:37 +0100" MODIFIED_BY="Emma Welsh" NOTES="&lt;p&gt;Exported from Review Manager 4.2.1&lt;br&gt;Short title (no longer in use): IV beta-agonists in acute asthma&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-02-10 11:26:31 +0000" NOTES_MODIFIED_BY="Emma Welsh" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.5">
<COVER_SHEET MODIFIED="2012-02-10 12:27:37 +0100" MODIFIED_BY="Emma Welsh">
<TITLE>Intravenous beta2-agonists for acute asthma in the emergency department</TITLE>
<CONTACT MODIFIED="2012-02-10 12:27:37 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="8615" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Travers</LAST_NAME><SUFFIX>BSc, MSc, MD, FRCPC(EM)</SUFFIX><POSITION>Provincial Medical Director</POSITION><EMAIL_1>Andrew.Travers@gov.ns.ca</EMAIL_1><MOBILE_PHONE>499-1634</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Emergency Medicine and Community Health and Epidemiology</DEPARTMENT><ORGANISATION>Emergency Health Services</ORGANISATION><CITY>Nova Scotia</CITY><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>pager 458-1538</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-02-10 12:27:37 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="8615" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Travers</LAST_NAME><SUFFIX>BSc, MSc, MD, FRCPC(EM)</SUFFIX><POSITION>Provincial Medical Director</POSITION><EMAIL_1>Andrew.Travers@gov.ns.ca</EMAIL_1><MOBILE_PHONE>499-1634</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Emergency Medicine and Community Health and Epidemiology</DEPARTMENT><ORGANISATION>Emergency Health Services</ORGANISATION><CITY>Nova Scotia</CITY><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>pager 458-1538</PHONE_1></ADDRESS></PERSON><PERSON ID="12437" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arthur</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Jones</LAST_NAME><SUFFIX>EdD, RRT</SUFFIX><EMAIL_1>jonesapjr@comcast.net</EMAIL_1><EMAIL_2>jonesapjr@yahoo.com</EMAIL_2><ADDRESS><ORGANISATION/><ADDRESS_1>3224 Sarmiento Drive</ADDRESS_1><CITY>Bensalem</CITY><ZIP>19020</ZIP><REGION>PA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+ 1 215 752 3165</PHONE_1><FAX_1>+ 1  215 752 1081</FAX_1></ADDRESS></PERSON><PERSON ID="12440" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Karen</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Kelly</LAST_NAME><SUFFIX>BScN PhD</SUFFIX><POSITION>Associate Professor</POSITION><EMAIL_1>karen.kelly@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Nursing</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>3rd Floor, Clinical Sciences Building</ADDRESS_1><CITY>Edmonton</CITY><ZIP>T6G 2G3</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 492 2697</PHONE_1><FAX_1>+1 780 492 2551</FAX_1></ADDRESS></PERSON><PERSON ID="55887BAA82E26AA20178986BA5476D18" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carlos</FIRST_NAME><MIDDLE_INITIALS>A Jr</MIDDLE_INITIALS><LAST_NAME>Camargo</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>ccamargo@partners.org</EMAIL_1><URL>www.emnet-usa.org</URL><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>Massachusetts General Hospital</ORGANISATION><ADDRESS_1>326 Cambridge St, Suite 410</ADDRESS_1><CITY>Boston</CITY><ZIP>02114</ZIP><REGION>Massachusetts</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+001 617 726 5276</PHONE_1><FAX_1>+001 617 724 4050</FAX_1></ADDRESS></PERSON><PERSON ID="19390" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Samantha</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Barker</LAST_NAME><ADDRESS><ORGANISATION>University of Alberta</ORGANISATION><CITY>Edmonton</CITY><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>780.407.6907</PHONE_1><FAX_1>780.407.3853</FAX_1></ADDRESS></PERSON><PERSON ID="FB72D3DD82E26AA20100F9CCFABFA64F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Brian</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Rowe</LAST_NAME><SUFFIX>MD, MSc, CCFP (EM), FCCP (BR)</SUFFIX><POSITION>Professor and Research Director</POSITION><EMAIL_1>brian.rowe@ualberta.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Emergency Medicine</DEPARTMENT><ORGANISATION>University of Alberta</ORGANISATION><ADDRESS_1>Room 1G1.43 Walter C. Mackenzie Health Sciences Centre</ADDRESS_1><ADDRESS_2>8440  112th Street</ADDRESS_2><CITY>Edmonton</CITY><ZIP>T6G 2B7</ZIP><REGION>Alberta</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 780 407 6707</PHONE_1><PHONE_2>+1 780 407 6761</PHONE_2><FAX_1>+1 780 407 3982</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-08-01 10:14:48 +0100" MODIFIED_BY="Toby Lasserson">
<UP_TO_DATE>
<DATE DAY="14" MONTH="10" YEAR="2000"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="10" YEAR="2000"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2012-02-10 11:26:13 +0000" MODIFIED_BY="Emma J Welsh" NOTES="&lt;p&gt;This is the first version of the review on the Cochrane Library.&lt;/p&gt;" NOTES_MODIFIED="2012-02-10 11:26:13 +0000" NOTES_MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2012-02-10 11:26:13 +0000" MODIFIED_BY="Emma J Welsh">
<DATE DAY="7" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>This review is no longer being updated as it is out of date. The review is being replaced by two new reviews with the titles "Intravenous beta2-agonists versus intravenous aminophylline for acute asthma" and "Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma".</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-02-07 11:22:23 +0000" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-02-07 11:22:23 +0000" MODIFIED_BY="Emma J Welsh">
<DATE DAY="1" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="10" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Alberta, Faculty of Medicine &amp; Dentistry</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Alberta Heritage Foundation for Medical Research (AHFMR)</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>NHS Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Canadian Association of Emergency Physicians (CAEP)</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>National Heart, Lung and Blood Institute (HL-03533 NIH; CA Camargo, Jr)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-02-10 11:26:31 +0000" MODIFIED_BY="Toby J Lasserson">
<SUMMARY MODIFIED="2008-08-01 09:38:05 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-08-01 09:38:05 +0100" MODIFIED_BY="Toby J Lasserson">Intravenous beta2-agonists for acute asthma in the emergency department</TITLE>
<SUMMARY_BODY>
<P>Beta2-agonist drugs form one of the mainstays of the treatment of acute severe asthma. They may be given by the inhaled or intravenous route. This review examined all the randomised controlled trials of the use of intravenous beta2-agonists in acute asthma and found no evidence to support its use.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-02-10 11:26:31 +0000" MODIFIED_BY="Emma J Welsh">
<ABS_BACKGROUND>
<P>Inhaled beta-agonist therapy is central to the management of acute asthma. The use of intravenous beta-agonist agents may also be beneficial in this setting.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the benefit of intravenous (IV) beta2-agonists for severe acute asthma treated in the emergency department.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Randomised controlled trials (RCT) were identified using the Cochrane Airways Group Register which is a compilation of systematic searches of MEDLINE, EMBASE, CINAHL, and CENTRAL as well as hand searching of 20 respiratory journals. Bibliographies from included studies and known reviews were also searched. Primary authors and content experts were contacted to identify eligible studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Only RCTs were considered for inclusion. Studies were included if patients presented to the emergency department with acute asthma and were treated with IV selective or nonselective beta2-agonists versus placebo, inhaled beta2-agonists, or other standard of care. Pulmonary function, vital signs, arterial gasses, adverse effects, and/or clinical success could be reported as outcome measures. Two reviewers independently selected potentially relevant articles and selected articles for inclusion. Methodological quality was independently assessed using two scoring systems and two reviewers.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted independently by two reviewers, and confirmed with corresponding authors. Missing data were obtained from authors or calculated from data present in the papers. Trials were combined using a random effects model for odds ratios (OR) or weighted mean differences (WMD) and reported with 95% confidence intervals (95% CI). </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-02-10 11:26:31 +0000" MODIFIED_BY="Emma J Welsh">
<P>From 746 identified references, 55 potentially relevant articles were identified and 15 were included. The trials included 584 patients. Overall, selective IV beta2-agonist use conferred no advantage over the comparator regimes. For example, it was associated with a lower PEFR after 60 minutes compared to inhaled beta2-agonist, although the difference was not statistically significant (-24.7 l/min; 95%CI 2.9, -52.3). There was no difference in heart rate (4.5 bpm; 95% CI -4.9, 14.0). In the well performed blinded studies there was no difference in autonomic side effects between treatments (Odds Ratio 2.2 (95%CI 0.9, 5.7).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is no evidence to support the use of IV beta2-agonists in patients with severe acute asthma. These drugs should be given by inhalation. No subgroups were identified in which the IV route should be considered. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-01 09:51:49 +0100" MODIFIED_BY="Toby J Lasserson">
<BACKGROUND>
<P>The general approach to treating patients with severe acute asthma is to use beta2-agonist bronchodilators and corticosteroids. For rapid bronchodilatation, penetration of inhaled drug to the affected small conducting airways may be impeded, and consequently responses may be a result of drug reaching the receptors via the systemic circulation. In these circumstances, if bronchodilatation occurs predominantly in response to the systemic distribution of the drug, intravenous (IV) rather than inhaled administration of bronchodilators may provide an earlier clinical response (<LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>). The research investigating the role of IV beta2-agonists in the emergent treatment of asthma has spanned more than 25 years. At present, each of the guidelines in North America and Europe recommend inhaled beta2-agonist therapy for all cases of asthma that present to the emergency department (<LINK REF="REF-Lipworth-1997" TYPE="REFERENCE">Lipworth 1997</LINK>; <LINK REF="REF-Beveridge-1996" TYPE="REFERENCE">Beveridge 1996</LINK>; <LINK REF="REF-Ernst-1996" TYPE="REFERENCE">Ernst 1996</LINK>; <LINK REF="REF-NAEPP-1997" TYPE="REFERENCE">NAEPP 1997</LINK>). IV and subcutaneous (SC) beta2-agonists are described as second line therapy for use in patients unresponsive to inhaled bronchodilator and systemic corticosteroid therapy, or if the inhaled route is not practical for the patient (<LINK REF="REF-Lipworth-1997" TYPE="REFERENCE">Lipworth 1997</LINK>; <LINK REF="REF-Beveridge-1996" TYPE="REFERENCE">Beveridge 1996</LINK>; <LINK REF="REF-Ernst-1996" TYPE="REFERENCE">Ernst 1996</LINK>; <LINK REF="REF-NAEPP-1997" TYPE="REFERENCE">NAEPP 1997</LINK>). However, debate regarding the benefit of this route of delivery remains. No systematic review of the IV beta2-agonist literature for the treatment of asthmatic exacerbations has been published to date.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this review was to determine if the evidence from randomised trials supports the use of IV beta2-agonists in the treatment of patients with severe acute asthma who present to the emergency department (ED). The questions specifically addressed are: <BR/>1. What is the clinical effect of administration of IV beta2-agonists on pulmonary function tests, laboratory parameters, vital signs, adverse effects, and clinical improvement/failure? <BR/>2. Does the age of the patient, beta2-agonist type (selective, nonselective), treatment strategy (Strategy I: IV vs. inhaled beta2-agonist; Strategy II: IV with inhaled vs. inhaled beta2-agonist, Strategy III: IV beta2-agonist vs. IV methylxanthine) or rate of administration influence the magnitude of effect? <BR/>3. Is the magnitude of effect influenced by the methodological quality of the included studies or the statistical model used for analysis?</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-01 09:40:25 +0100" MODIFIED_BY="Toby J Lasserson">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>To be considered for review, studies had to be randomised controlled trials (RCTs) or quasi RCTs (allocation on days of the week, or some other method).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Studies of adult or pediatric patients with severe acute asthma presenting to an emergency room (or its equivalent) were considered.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The target intervention was the administration of IV selective or non-selective beta2-agonists. The control intervention was the administration of placebo, other intravenous bronchodilators (i.e. methylxanthines), or other inhaled selective or nonselective beta2-agonists. Included studies could also use other recognised standards of care (i.e. corticosteroids).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Pulmonary functions, vital signs, adverse effects and clinical scores. </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-01 09:38:42 +0100" MODIFIED_BY="Toby J Lasserson">
<ELECTRONIC_SEARCHES MODIFIED="2008-08-01 09:38:36 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Randomised controlled trials were identified in the both the Cochrane Airways Review Group database and Cochrane Controlled Trials Register (CCTR) using the following search strategy: (placebo* OR trial* OR random* OR double-blind OR double blind OR single-blind OR single blind OR controlled study OR comparative study). An advanced search of this database, and the Cochrane Controlled Trials Register, was completed using the following terms:</P>
<P>(1) Asthma OR Wheez* AND<BR/>(2) Emerg* OR acute* OR status* AND<BR/>(3) Discharge* OR admi* OR hospit* AND<BR/>(4) beta-agonist OR betaagonist OR beta agonist OR bronchodilat* OR adrenaline OR albuterol OR bricanyl OR epinephrine OR isoprenaline OR isoproterenol OR hexoprenaline OR reproterol OR salbutamol OR terbutaline OR ventolin OR *erol. Several other databases were also searched separately using the same search terms, including: MEDLINE, EMBASE, CINAHL, and Current Contents. Reference lists of all available primary studies and review articles were reviewed to identify potential relevant citations. Trials were not excluded on the basis of language.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-08-01 09:38:41 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Inquiries regarding other published or unpublished studies known and/or supported by the authors of the primary studies were made so that these results could be included in this review. Several pathways were used to locate authors including letters to an address presented in the article, Internet 'People and Hospital Searches', electronic author searches in library databases for the address on the most recent article published by the author, and contact with other reviewers on the ARG. Scientific advisors of the various pharmaceutical companies (Glaxo) that manufacture beta2-agonists were contacted for any unpublished, published, or interim results on beta2-agonist research. Personal contact with colleagues, collaborators and other trialists working in the field of asthma was made to identify potentially relevant studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-01 09:40:25 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_SELECTION MODIFIED="2008-08-01 09:39:09 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The reference lists from the search strategy was independently reviewed by two researchers (AHT, BHR), and clearly irrelevant articles were discarded. If the title, abstract, or descriptors suggested any potential relevance, the full text article was retrieved. Agreement for relevance was measured using kappa statistics. Each relevant paper was then assessed by two independent reviewers (BHR, AJ) for inclusion in this review. The reviewers were not blinded to the authors, journal of publication, or results of the studies as investigator bias was deemed unlikely. Agreement for final inclusion was measured using kappa statistics. Disagreement was resolved by consensus or third party adjudication (AHT).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-08-01 09:39:33 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Data for the trials were independently extracted by two reviewers (AHT, CS) and entered (SJB) into the Cochrane Collaboration software program (Review Manager Version 4.0.4). Primary study authors were requested to confirm data extraction and provide additional clarification or information for the review. In cases where tables were unavailable, graphs were enlarged and values were approximated. This technique was required for seven studies (<LINK REF="STD-Hambleton-1979" TYPE="STUDY">Hambleton 1979</LINK>; <LINK REF="STD-Hussein-1986" TYPE="STUDY">Hussein 1986</LINK>; <LINK REF="STD-Johnson-1978" TYPE="STUDY">Johnson 1978</LINK>; <LINK REF="STD-Swedish-Society-1990" TYPE="STUDY">Swedish Society 1990</LINK>; <LINK REF="STD-Tribe-1976" TYPE="STUDY">Tribe 1976</LINK>; <LINK REF="STD-Van-Renterghem-1987" TYPE="STUDY">Van Renterghem 1987</LINK>; <LINK REF="STD-Williams-1981" TYPE="STUDY">Williams 1981</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-08-01 09:39:21 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Assessment of Methodological Quality: The methodological quality of each included paper was assessed independently by two reviewers, using two methods of quality assessment. In the first method, two reviewers (CC and AJ) used the Cochrane approach to assessment of allocation concealment:<BR/>
</P>
<UL>
<LI>Grade A: Adequate concealment</LI>
<LI>Grade B: Uncertain</LI>
<LI>Grade C: Clearly inadequate concealment</LI>
</UL>
<P>In the second method, two reviewers (AHT, CS) used the Jadad Criteria for methodological quality (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). Using this tool, one point is allocated each for randomisation, blinding, and description of withdrawals and dropouts. An extra point is added for both methods of randomisation and blinding that are well described and adequate, whereas a point is deducted if the methods are considered inadequate. The maximum score is five points and studies scoring 3 or more are regarded as being of high methodological quality. Using either method, inter-rater reliability was measured by using simple agreement, kappa, and weighted kappa statistics, and disagreement was resolved by third party adjudication (BHR).</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-08-01 09:39:48 +0100" MODIFIED_BY="Toby J Lasserson">
<P>All trials were combined using the Review Manager 4.0.4. For continuous variables, a random effects weighted mean difference (WMD) and 95% confidence interval (CI) were calculated for each study. For dichotomous variables, a random effects odds ratio (OR, 95% CI) was calculated for individual studies. All similar studies were pooled using random effects OR or WMD and 95% CIs.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-08-01 09:40:03 +0100" MODIFIED_BY="Toby J Lasserson">
<P>For pooled effects, heterogeneity was tested using the Breslow-Day test; p &lt; 0.05 was considered statistically significant. For those main outcome measures with statistical heterogeneity, a priori subgroup analyses were divided on the following basis:</P>
<P>(a) Population: adult vs. pediatric<BR/>(b) Population: severity of illness based on PFTs<BR/>(c) Intervention: selective vs. nonselective beta2-agonists<BR/>(d) Intervention: IV vs. inhaled beta2-agonists<BR/>(e) Intervention: IV with inhaled vs. inhaled beta2-agonists<BR/>(f) Intervention: IV beta2-agonists vs. IV methylxanthines<BR/>(g) Intervention: infusion vs. bolus beta2-agonists</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-08-01 09:40:20 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Sensitivity analyses were completed on the strength of methodological quality (high vs. low) and statistical method of analysis (random versus fixed effects).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-01 09:51:49 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION MODIFIED="2008-08-01 09:42:19 +0100" MODIFIED_BY="Toby J Lasserson">
<SEARCH_RESULTS MODIFIED="2008-08-01 09:41:01 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The ARG database search revealed 976 references which represented 740 (76%) original publications: 258 (35%) in EMBASE; 250 (34%) in MEDLINE; 2 (0.3%) from CINAHL; 224 (30%) from both MEDLINE and EMBASE; and 6 references (0.7%) were cited in all three. Independent review of the abstracts and titles of these publications identified 31 potentially relevant studies. The agreement for relevance was high (kappa: 0.83). Twenty-four additional references were added from bibliographic searching of relevant articles and overviews; a total of 55 papers were reviewed for inclusion. Unpublished literature was requested from pharmaceutical companies and the authors of all included studies, but none were identified. Of these 55 articles, a total of fifteen studies (27%) were included in the overview (k = 0.87).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-08-01 09:42:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The evidence for intervention with IV beta2-agonists spans a period of twenty-five years: 7 (47%) articles published in the 1970s, 5 (33%) papers in the 1980s, and 3 (20%) trials in the 1990s. Twelve (80%) of the studies were conducted in Europe, 1 (7%) in Asia, and 2 (13%) in Australia. No trials meeting our inclusion criteria were conducted in North America.</P>
<SUBSECTION>
<HEADING LEVEL="6">Study Design</HEADING>
<P>Thirteen (87%) of the studies followed a parallel protocol, whereas 2 (13%) of the studies followed a crossover model (<LINK REF="STD-Bloomfield-1979" TYPE="STUDY">Bloomfield 1979</LINK>; <LINK REF="STD-Tribe-1976" TYPE="STUDY">Tribe 1976</LINK>). Eleven (73%) studies introduced IV beta2-agonists immediately upon entry into the study. The remaining 4 papers introduced IV beta2-agonists 30 to 75 minutes after entry into the study, during which time the patients received either inhaled beta2-agonists (<LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>; <LINK REF="STD-Cheong-1988" TYPE="STUDY">Cheong 1988</LINK>; <LINK REF="STD-Van-Renterghem-1987" TYPE="STUDY">Van Renterghem 1987</LINK>) or IV aminophylline (<LINK REF="STD-Johnson-1978" TYPE="STUDY">Johnson 1978</LINK>).</P>
<P>There were three main treatment strategies utilized in the studies under review. Three papers utilized Strategy I in which IV beta2-agonists were compared to inhaled beta2-agonist, where both groups of patients received a run in of inhaled beta2-agonist therapy (<LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>; <LINK REF="STD-Cheong-1988" TYPE="STUDY">Cheong 1988</LINK>; <LINK REF="STD-Van-Renterghem-1987" TYPE="STUDY">Van Renterghem 1987</LINK>). Essentially, this was equivalent to comparing IV beta2-agonists and standard of care with standard of care alone. Six papers utilised Strategy II, where IV beta2-agonists were compared with inhaled agents, with no inhalational therapy in the IV beta2-agonist arm (<LINK REF="STD-Bloomfield-1979" TYPE="STUDY">Bloomfield 1979</LINK>; <LINK REF="STD-Hussein-1986" TYPE="STUDY">Hussein 1986</LINK>; <LINK REF="STD-Lawford-1978" TYPE="STUDY">Lawford 1978</LINK>; <LINK REF="STD-Salmeron-1994" TYPE="STUDY">Salmeron 1994</LINK>; <LINK REF="STD-Swedish-Society-1990" TYPE="STUDY">Swedish Society 1990</LINK>; <LINK REF="STD-Williams-1981" TYPE="STUDY">Williams 1981</LINK>) . Essentially this approach compared IV to inhaled beta2-agonist delivery. The remaining six papers utilised Strategy III, where IV beta2-agonists were compared with IV methylxanthines, where neither group received inhaled beta2-agonist therapy (<LINK REF="STD-Femi_x002d_Pearse-1-1977" TYPE="STUDY">Femi-Pearse 1 1977</LINK>; <LINK REF="STD-Hambleton-1979" TYPE="STUDY">Hambleton 1979</LINK>; <LINK REF="STD-Johnson-1978" TYPE="STUDY">Johnson 1978</LINK>; <LINK REF="STD-Sharma-1-1984" TYPE="STUDY">Sharma 1 1984</LINK>; <LINK REF="STD-Tribe-1976" TYPE="STUDY">Tribe 1976</LINK>; <LINK REF="STD-Williams-1975" TYPE="STUDY">Williams 1975</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Populations</HEADING>
<P>Participants were selected from a sample of patients who presented to the emergency department or its equivalent with severe acute asthma; all patients were admitted to hospital. The majority of studies focused on adult patients only (age range: 15 to 65 years), with only three papers enrolling children (age range: 0.8 to 14.7 years; <LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>; <LINK REF="STD-Hambleton-1979" TYPE="STUDY">Hambleton 1979</LINK>; <LINK REF="STD-Hussein-1986" TYPE="STUDY">Hussein 1986</LINK>). The pre-hospital asthma medication profile, and asthma history of the patients could not be easily determined from these studies. The median sample size across the studies was 23 with a range of 13 to 176 patients. All papers enrolled 'severe asthmatics'; however, there was variety in the parameters and definitions used for inclusion criteria. Nine papers used vital signs (heart rate greater than 100) and pulmonary function tests (PFT less than 20% expected) as primary inclusion criteria (<LINK REF="STD-Bloomfield-1979" TYPE="STUDY">Bloomfield 1979</LINK>; <LINK REF="STD-Cheong-1988" TYPE="STUDY">Cheong 1988</LINK>; <LINK REF="STD-Femi_x002d_Pearse-1-1977" TYPE="STUDY">Femi-Pearse 1 1977</LINK>; <LINK REF="STD-Lawford-1978" TYPE="STUDY">Lawford 1978</LINK>; <LINK REF="STD-Salmeron-1994" TYPE="STUDY">Salmeron 1994</LINK>; <LINK REF="STD-Swedish-Society-1990" TYPE="STUDY">Swedish Society 1990</LINK>; <LINK REF="STD-Van-Renterghem-1987" TYPE="STUDY">Van Renterghem 1987</LINK>; <LINK REF="STD-Williams-1975" TYPE="STUDY">Williams 1975</LINK>; <LINK REF="STD-Williams-1981" TYPE="STUDY">Williams 1981</LINK>). Five papers required abnormalities in arterial blood gas (ABG) measurements (<LINK REF="STD-Hambleton-1979" TYPE="STUDY">Hambleton 1979</LINK>; <LINK REF="STD-Salmeron-1994" TYPE="STUDY">Salmeron 1994</LINK>; <LINK REF="STD-Van-Renterghem-1987" TYPE="STUDY">Van Renterghem 1987</LINK>; <LINK REF="STD-Williams-1975" TYPE="STUDY">Williams 1975</LINK>; <LINK REF="STD-Williams-1981" TYPE="STUDY">Williams 1981</LINK>). Four papers listed simple clinical symptoms and signs of "severe shortness of breath or wheezing" as inclusion criteria (<LINK REF="STD-Johnson-1978" TYPE="STUDY">Johnson 1978</LINK>; <LINK REF="STD-Hambleton-1979" TYPE="STUDY">Hambleton 1979</LINK>; <LINK REF="STD-Sharma-1-1984" TYPE="STUDY">Sharma 1 1984</LINK>; <LINK REF="STD-Tribe-1976" TYPE="STUDY">Tribe 1976</LINK>). Two papers described standardized clinical assessment scales or definitions for severe asthma as inclusion criteria. One author utilized national guidelines (National Asthma Campaign, 1993) of any 4 features of respiratory distress (wheeze, sternal retraction, accessory muscle use, dyspnea) or any absolute criteria (cyanosis, pulsus paradox, altered level of consciousness, silent chest) (<LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>). Another author (<LINK REF="STD-Salmeron-1994" TYPE="STUDY">Salmeron 1994</LINK>), enrolled only those patients who met the definition for severe asthma as defined by the American Thoracic Society (<LINK REF="REF-ATS-1962" TYPE="REFERENCE">ATS 1962</LINK>).</P>
<P>In summary, despite the variability of definitions, based on review, all patients entered into these studies could be considered to be suffering "severe acute asthma" requiring admission to hospital as defined by the organizations involved in asthma care (<LINK REF="REF-Beveridge-1996" TYPE="REFERENCE">Beveridge 1996</LINK>; <LINK REF="REF-Ernst-1996" TYPE="REFERENCE">Ernst 1996</LINK>; <LINK REF="REF-Lipworth-1997" TYPE="REFERENCE">Lipworth 1997</LINK>; <LINK REF="REF-NAEPP-1997" TYPE="REFERENCE">NAEPP 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Interventions</HEADING>
<P>A variety of co-interventions were administered across studies; however, all patients received supplemental oxygen by face mask and systemic corticosteroids. Most of the trials introduced the corticosteroids to all patients on entry into the study, however in one study an unspecified dose of steroids was withheld until two hours into the study in only a selected subgroups of patients (<LINK REF="STD-Swedish-Society-1990" TYPE="STUDY">Swedish Society 1990</LINK>). No patients received inhaled steroids, or inhaled anticholinergic agents in any of the studies. All studies used selective beta2-agonists. Nine papers (<LINK REF="STD-Bloomfield-1979" TYPE="STUDY">Bloomfield 1979</LINK>; <LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>; <LINK REF="STD-Femi_x002d_Pearse-1-1977" TYPE="STUDY">Femi-Pearse 1 1977</LINK>; <LINK REF="STD-Hambleton-1979" TYPE="STUDY">Hambleton 1979</LINK>; <LINK REF="STD-Sharma-1-1984" TYPE="STUDY">Sharma 1 1984</LINK>; <LINK REF="STD-Swedish-Society-1990" TYPE="STUDY">Swedish Society 1990</LINK>; <LINK REF="STD-Tribe-1976" TYPE="STUDY">Tribe 1976</LINK>; <LINK REF="STD-Van-Renterghem-1987" TYPE="STUDY">Van Renterghem 1987</LINK>; <LINK REF="STD-Williams-1981" TYPE="STUDY">Williams 1981</LINK>) gave IV beta2-agonists as a bolus (range 100 - 500 ug, or 4 - 15 ug/kg) , whereas 6 studies (<LINK REF="STD-Cheong-1988" TYPE="STUDY">Cheong 1988</LINK>; <LINK REF="STD-Johnson-1978" TYPE="STUDY">Johnson 1978</LINK>; <LINK REF="STD-Hambleton-1979" TYPE="STUDY">Hambleton 1979</LINK>; <LINK REF="STD-Lawford-1978" TYPE="STUDY">Lawford 1978</LINK>; <LINK REF="STD-Salmeron-1994" TYPE="STUDY">Salmeron 1994</LINK>) administered the IV beta2-agonist as an infusion (range: 8.3 - 20 ug/min to total doses of 500 ug - 3000 ug). Most studies (73%) used salbutamol as the beta-agonist, except for 3 studies in which terbutaline was evaluated (<LINK REF="STD-Sharma-1-1984" TYPE="STUDY">Sharma 1 1984</LINK>; <LINK REF="STD-Van-Renterghem-1987" TYPE="STUDY">Van Renterghem 1987</LINK>; <LINK REF="STD-Williams-1975" TYPE="STUDY">Williams 1975</LINK>), and 1 study where reproterol was used (<LINK REF="STD-Hussein-1986" TYPE="STUDY">Hussein 1986</LINK>). One study ran a triple parallel protocol comparing IV salbutamol versus IV terbutaline versus IV aminophylline (<LINK REF="STD-Sharma-1-1984" TYPE="STUDY">Sharma 1 1984</LINK>). For this review, only the comparison of IV salbutamol versus aminophylline was included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcomes</HEADING>
<P>Each paper evaluated their primary outcomes within a two hour period. However, six papers extended the observation interval longer: 3 hours (<LINK REF="STD-Sharma-1-1984" TYPE="STUDY">Sharma 1 1984</LINK>), 5 hours (<LINK REF="STD-Cheong-1988" TYPE="STUDY">Cheong 1988</LINK>), 6 hours (<LINK REF="STD-Salmeron-1994" TYPE="STUDY">Salmeron 1994</LINK>), 24 hours (<LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>; <LINK REF="STD-Hambleton-1979" TYPE="STUDY">Hambleton 1979</LINK>), and 36 hours (<LINK REF="STD-Hussein-1986" TYPE="STUDY">Hussein 1986</LINK>; <LINK REF="STD-Johnson-1978" TYPE="STUDY">Johnson 1978</LINK>). Multiple statistical tests were performed in each study, with a mean of 24 (varying from 0 to 80). No mention of adjustments for multiple testing were identified in these papers, and 11 (73%) made no mention of possible type I errors.</P>
<P>Over 240 individual outcome measurements were abstracted from the studies. Scores from a variety of symptom scales were occasionally used to describe outcomes; however, due to the different scores used, no pooled analyses were conducted. In addition, a number of PFT results were employed (including PEFR, FEV1, FVC, % predicted PEFR, % predicted FEV1), however variability in the type of PFT employed limited comparisons between studies. There were no descriptions of any patients who were intubated or died during any of the study observation periods. Five trials used improvements in PFTs (namely PEFR) as the primary outcome (<LINK REF="STD-Bloomfield-1979" TYPE="STUDY">Bloomfield 1979</LINK>; <LINK REF="STD-Cheong-1988" TYPE="STUDY">Cheong 1988</LINK>; <LINK REF="STD-Johnson-1978" TYPE="STUDY">Johnson 1978</LINK>; <LINK REF="STD-Williams-1975" TYPE="STUDY">Williams 1975</LINK>; <LINK REF="STD-Williams-1981" TYPE="STUDY">Williams 1981</LINK>). Five papers described a primary outcome variable of "Clinical Improvement"; however, the definition varied widely between papers. Three of these relied on the 'impression by the patient or physician of improvement in symptoms' (<LINK REF="STD-Lawford-1978" TYPE="STUDY">Lawford 1978</LINK>; <LINK REF="STD-Swedish-Society-1990" TYPE="STUDY">Swedish Society 1990</LINK>; <LINK REF="STD-Tribe-1976" TYPE="STUDY">Tribe 1976</LINK>). The remaining two papers used predefined clinical determinants of success (<LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>; <LINK REF="STD-Salmeron-1994" TYPE="STUDY">Salmeron 1994</LINK>). The first defined three unique primary clinical measures of success: earlier ED discharge time (defined as the start of hourly inhaled salbutamol therapy), faster recovery time (to cessation of nebulised beta2-agonists every thirty minutes, and sixty minutes), and less oxygen dependence (defined at the two hour window as the requirement for medical oxygen to maintain oxygen saturations above 93%) (<LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>). The second paper defined 'Clinical Success' as the presence of at least two of the following points at 60 minutes: (1) a decrease in a "clinical index rating" of at least three points; (2) a decrease in PaCO2 of at least three mm Hg; (3) an increase in PEFR of at least 50 L/min (<LINK REF="STD-Salmeron-1994" TYPE="STUDY">Salmeron 1994</LINK>).</P>
<P>Consequent to the variety of outcomes, only seven domains were analysed where data were sufficiently available and similarly derived:<BR/>(a) serial PEFR<BR/>(b) serial % predicted PEFR<BR/>(c) serial FEV1<BR/>(d) serial HR<BR/>(e) autonomic side effects<BR/>(f) Clinical Success<BR/>(g) arterial gas values</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-08-01 09:41:12 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Of the 40 studies which were excluded, 30 (55%) were non-randomised, 7 (13%) included treatment of non-acute asthmatics or non-asthmatics, 3 (5%) examined non-IV routes of administration. The ARG database identified 12 (80%) of the included articles: six were from MEDLINE (<LINK REF="STD-Bloomfield-1979" TYPE="STUDY">Bloomfield 1979</LINK>; <LINK REF="STD-Johnson-1978" TYPE="STUDY">Johnson 1978</LINK>; <LINK REF="STD-Tribe-1976" TYPE="STUDY">Tribe 1976</LINK>; <LINK REF="STD-Williams-1975" TYPE="STUDY">Williams 1975</LINK>; <LINK REF="STD-Williams-1981" TYPE="STUDY">Williams 1981</LINK>; <LINK REF="STD-Sharma-1-1984" TYPE="STUDY">Sharma 1 1984</LINK>), two from EMBASE (<LINK REF="STD-Van-Renterghem-1987" TYPE="STUDY">Van Renterghem 1987</LINK>; <LINK REF="STD-Hussein-1986" TYPE="STUDY">Hussein 1986</LINK>), and four from both (<LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>; <LINK REF="STD-Cheong-1988" TYPE="STUDY">Cheong 1988</LINK>; <LINK REF="STD-Salmeron-1994" TYPE="STUDY">Salmeron 1994</LINK>; <LINK REF="STD-Swedish-Society-1990" TYPE="STUDY">Swedish Society 1990</LINK>). The remaining three papers were found from separate MEDLINE searches (<LINK REF="STD-Lawford-1978" TYPE="STUDY">Lawford 1978</LINK>; <LINK REF="STD-Femi_x002d_Pearse-1-1977" TYPE="STUDY">Femi-Pearse 1 1977</LINK>; <LINK REF="STD-Hambleton-1979" TYPE="STUDY">Hambleton 1979</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Many of the included papers were double-blind, placebo controlled trials, however the methodological quality varied across studies. Using the Jadad method, 7 studies were rated as "strong" (47%) and 8 (53%) were rated as "weak" (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). Agreement between the two independent assessments of study quality was high (kappa ranged from 0.59 to 1.0 for each domain). There was no significant correlation between quality scores and the year of publication of the trial (Pearson r = 0.38, p=0.17). Using the Cochrane methodology, 5 papers (33%) were rated as having clearly blinded allocation and 10 (67%) were rated as having unclear allocation blinding (kappa = 1.0). There was no statistically significant association between those papers that were rated as strong methodologically and those that had blinded allocation (Chi square 2.04; df=1; p&gt;0.05).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-01 09:51:49 +0100" MODIFIED_BY="Toby J Lasserson">
<P>NOTE: data are entered into the graphs as negative values, to allow the graphs to conform to the 'Cochrane convention' that beneficial changes associated with the treatment under review go to the left of the no difference line.</P>
<SUBSECTION>
<HEADING LEVEL="4">OBJECTIVE ONE: COMBINED RESULTS FOR ALL TREATMENT OPTIONS</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Pulmonary Function</HEADING>
<P>Across the six hours observation in the seven papers reporting PEFR, no statistical differences in PEFR were identified between those patients who received IV beta2-agonists versus inhaled beta2-agonists or IV methylxanthines. Moreover, differences between the summary outcome measures in each time point were also of questionable clinical significance with pooled estimates of treatment effect ranging from -0.42 L/min to 19.42 L/min. The heterogeneity present in the 60 and 120 minute time points is addressed in the sensitivity analysis later in this section. It should be noted that in the comparisons with inhaled therapy, this treatment produced a significantly greater increase in PEFR at 60 minutes compared to the IV route, when a random effects model was used, although there was heterogeneity in size of effect between trials.</P>
<P>Three papers reported serial changes in percent predicted peak expiratory flow rates. Although there was no statistically significant difference between treatments over six hours, the results demonstrated an increasing treatment effect over a six hour period favouring IV beta2-agonists (compare -1.42% at one hour versus -8.75% at six hours). However, such marginal differences in percent predicted PEFR are of questionable clinical importance. There was no visual or statistical heterogeneity across the time points in this analysis. Two papers reported serial changes in forced expiratory volume in one second. Over six hours there were no statistically or clinically significant differences with respect to FEV1.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Serial Heart Rates</HEADING>
<P>Nine papers described heart rate results over a six hour period. Over this time there were lower heart rates in those patients who received the comparison treatment (range 3.95 to 12.26 beats per minute). These differences were statistically significant in the 15 and 45 minute period, and the 2-6 hour time points, each of which were homogeneous pooled estimates. However, the differences in heart rates are of questionable clinical significance.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Arterial Blood Gas Measurements</HEADING>
<P>Six papers described arterial blood gas measurements for oxygen tensions, and five papers described carbon dioxide tensions all within a two hour period. There was no statistical difference in either the arterial oxygen tension, or carbon dioxide tension between IV beta2-agonists and comparison treatments. Furthermore, there was no heterogeneity across any time point.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Autonomic Side Effects</HEADING>
<P>Despite concern regarding the potential side effects of IV beta2-agonists, only 10 (67%) studies reported this information. Autonomic effects included: cardiovascular (palpitations, tachycardia, hypertension), neurological (tremor, headache), and/or gastrointestinal (nausea, vomiting). The pooled OR suggests that the proportion of patients who experienced adverse effects from IV treatment were approximately twice as frequent as those who received the comparison treatment. However, this result was not statistically significant and significant heterogeneity was present in the pooled estimate (Chi square 36.8; df=8; p &lt; 0.05 ).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Clinical Failure</HEADING>
<P>Five papers reported a primary outcome variable of "Clinical Improvement", however there was variability in the subjective and objective measures used. The pooled OR suggests that the proportion of patients who failed to improve with IV therapy was the same as the proportion who received the comparison treatment. However, significant heterogeneity was present in the pooled estimate (Chi square 24.48; df=4; p &lt; 0.05 ).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">OBJECTIVE TWO: SUBGROUP &amp; SENSITIVITY ANALYSES</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">SUBGROUP ANALYSIS</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Population</HEADING>
<P>An insufficient number of pediatric papers with similar outcome measures were identified and this precluded any subgroup comparison on the basis of age. Only three of the fifteen included papers (20%) evaluated the pediatric population (<LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>; <LINK REF="STD-Hussein-1986" TYPE="STUDY">Hussein 1986</LINK>; <LINK REF="STD-Hambleton-1979" TYPE="STUDY">Hambleton 1979</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Intervention</HEADING>
<P>Three types of beta2-agonists were evaluated - the majority examined salbutamol; however, terbutaline was reviewed in three papers (<LINK REF="STD-Sharma-1-1984" TYPE="STUDY">Sharma 1 1984</LINK>; <LINK REF="STD-Van-Renterghem-1987" TYPE="STUDY">Van Renterghem 1987</LINK>; <LINK REF="STD-Williams-1981" TYPE="STUDY">Williams 1981</LINK>), and reproterol in one paper (<LINK REF="STD-Hussein-1986" TYPE="STUDY">Hussein 1986</LINK>). An insufficient number of similar outcomes prevented any formal comparison of results based on drug type. There was no statistical difference in any of the outcome domains when comparing beta2-agonists administered as an IV bolus versus infusion. Three of the 15 papers evaluated the question of whether IV beta2-agonists improve the initial bronchodilator response when given in addition to nebulised beta2-agonist therapy (Strategy I). Amongst these studies, the only domain where sufficient similar outcomes were reported, were in two papers in the time point of %predicted PEFR (<LINK REF="STD-Cheong-1988" TYPE="STUDY">Cheong 1988</LINK>; <LINK REF="STD-Van-Renterghem-1987" TYPE="STUDY">Van Renterghem 1987</LINK>). In this time point there was no significant improvement at each point in time, and the changes that were identified would be clinically insignificant. In the remaining paper utilizing treatment Strategy I, there were no reports of pulmonary function data thereby limiting comparisons with the other two papers (<LINK REF="STD-Browne-1997" TYPE="STUDY">Browne 1997</LINK>). There was no change in the trends of the summary statistics for any of the outcome domains when Strategy II was compared to Strategy III. Too few studies with sufficient similar outcomes limited any meaningful comparison of Strategy I versus Strategy III.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">SENSITIVITY ANALYSIS</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Methodological Quality</HEADING>
<P>Using Jadad's methods a strong methodological paper was defined as having a Jadad score of 3 to 5, and a weak paper as having a Jadad score of 0 to 2. This sensitivity analysis helps to explain much of the heterogeneity observed above. It is evident that the methodologically stronger papers fail to demonstrate a clinical or statistical difference between IV agents or the comparison treatment arm in terms of PEFR and clinical success. Moreover, although not statistically significant, IV beta2-agonists appear to have an increased risk of adverse effects and increased heart rate compared to the control treatment in this analysis. By comparing the two groups it is clear that the weak methodological papers had larger effects, favouring the comparison treatment. Sensitivity analysis by fixed effects modelling demonstrated no differences in results except for more time points with statistically significant lower serial heart rates for the non-IV groups (range: 0.1 to 14.1 beats/min).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-01 09:43:35 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The literature is conflicting regarding the use of IV agents, and this systematic overview is the first to examine evidence of the effect of treating asthmatics with IV beta2-agonists following diagnosis in the ED. The review included fifteen randomised parallel and crossover trials over twenty-five years that included 584 adults and children across nine countries. Several important points arise. First, there was no statistically significant difference in effect between IV beta2-agonists and all other treatments combined (inhaled beta2-agonists, or IV methylxanthines). Second, intravenous beta2-agonists administered either by bolus or infusion did not lead to significant improvements in any of the outcome measures of clinical success. Third, the use of IV beta2-agonists was associated with an non-significant increase in risk of autonomic side effects (2-12 times), and higher heart rates (4-10 beats per minute). Finally, there were no sub-groups in which this agent was shown to be effective.</P>
<P>It should be noted that when using a fixed effects model, inhaled beta2-agonist produced a significantly greater mean improvement at 60 mins than the IV route, but there was significant heterogeneity between studies, and the trials of poorer quality had a larger effect of inhaled therapy than IV therapy.</P>
<P>When examining the quality of papers involving IV agents in acute asthmatic presentations, it is obvious that greater care must be incorporated into further work if clarity is to emerge. There were broad discrepancies among outcomes from studies where methodological quality was scored using two accepted methods (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>; <LINK REF="REF-Mulrow-1999" TYPE="REFERENCE">Mulrow 1999</LINK>). Moreover, statistical planning and sample size calculations were not carefully considered in most studies. No papers were large enough to protect against type II error, and sample size calculations were rarely reported. Furthermore, multiple statistical testing was performed in many studies, increasing the risk of type I error. Factors confounding the relationship of IV beta2-agonists use and outcome measures are the weak methodologies of the studies included in the summary measures. When analysed by methodological quality, the treatment effects were less pronounced in the methodologically stronger studies.</P>
<P>Trials involving IV beta2-agonists could be grouped into three categories. Historically, the first studies compared IV beta2-agonists with IV aminophylline (40% of the included papers in this review). However, as practice has changed, the routine use of aminophylline has diminished, and inhaled IV beta2-agonists have been increasingly used. Consequently, a shift in focus to compare IV versus nebulised beta2-agonists (40% of the included papers) occurred. However, the question whether IV beta2-agonists improve bronchodilator response when given in addition to nebulised bronchodilators was only addressed in 20% (3/15) of the studies under review. These trials evaluated differing age groups (two adult and one pediatric population) using different primary outcomes. This limited the conclusions that could be drawn from pooling of results. Consequently, although the evidence suggests that IV beta2-agonists alone are no better than the inhaled route of delivery, the role of IV beta2-agonists in addition to inhaled beta2-agonists remains unclear.</P>
<SUBSECTION>
<HEADING LEVEL="6">Methodological limitations</HEADING>
<P>One potential concern in this systematic review is the pooling of results. The review identified 15 RCTs dealing with the use of IV beta2-agonists in severe acute asthma. The review authors evaluated the studies and concluded it would be sensible and efficient to combine these studies, since the sample sizes of the individual studies were insufficient to reach a firm conclusion on their own. In addition, the decision to combine results was based on demonstration of similarities in populations, interventions, and outcome measurements between studies. By dividing the papers into their respective categories, the issue of similarity was addressed. As a result of these steps, we feel the pooling of data was reasonable. Despite these features, statistically significant heterogeneity was still found in some of the analyses.</P>
<P>Due to the small number of trials included in this meta-analysis, and the overall small number of patients upon which the results are based, no firm conclusions regarding subgroups by treatment (i.e. IV with nebuliser versus IV without nebuliser) or age could be made. Also, this review analysed only the IV route of administration, and did not evaluate trials of subcutaneous routes of administration. While there was significant heterogeneity in pooled estimates for many of the outcome time points, upon further sensitivity analysis it appeared that papers of low methodological quality accounted for most of this heterogeneity. In particular, one paper (<LINK REF="STD-Swedish-Society-1990" TYPE="STUDY">Swedish Society 1990</LINK>) was responsible for the majority of the heterogeneity based on the following points: (1) Differential Methodological Quality: The Swedish Society paper was rated as the weakest paper amongst those in the review (Jadad score = 1 ); (2) Different Populations: All papers studied extremely severe asthmatic patients, however the majority of papers enrolled patients with mean PEFRs in the range of 50 to 100 L/min, whereas the Swedish study evaluated patients with mean PEFRs in the 160 to 170 l/min range (still defined as "severe &lt; 200 L/min" by international guidelines). (3) Different co-interventions: The Swedish study did not administer any steroid therapy until two hours into the study protocol, whereas all other papers introduced steroid therapy at time of enrolment into the study. The effects of each of these factors on the homogeneity of the outcome domains were confounding in isolation and in whole by the very large sample size of the Swedish study (n=176) in relation to the relatively smaller studies (range n=14 to 71).</P>
<P>Despite the intensive search strategy employed, there still exists a possibility of study selection bias or publication bias in this meta-analysis. For example, through missing unpublished negative or positive trials we may be erroneously estimating the non-significant effects of IV beta2-agonists. However, a comprehensive search of the published English and non-English literature for potentially relevant studies was conducted, using a systematic search strategy to avoid bias. In addition, attempts were made to contact first and corresponding authors. Despite these endeavours, no unpublished or non-English papers were uncovered; however, we recognize that they may exist.</P>
<P>Finally, the outcome measure for "success" in treating acute asthma was measured variably between studies, and perhaps also within studies (particularly in those studies relying on the subjective impression of improvement by the patient or physician). Better standardization of this outcome would improve study comparability. Most studies included PFT outcome measures, namely: absolute PEFR, percent change in predicted PEFR, FEV1, or percent change in predicted FEV1. Here again standardisation of reporting would allow better comparisons between trials. Evaluation of adverse side effects was complicated by a lack of standardized reporting.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-08-01 09:44:07 +0100" MODIFIED_BY="Toby J Lasserson">
<IMPLICATIONS_PRACTICE>
<P>[1] Intravenous beta2-agonist used either as an adjunct to, or replacement of, inhaled bronchodilator therapy appears to offer no clinical benefit in acute asthma.<BR/>[2] The benefit of IV therapy in ventilated patients has not been examined. <BR/>[3] Efficacy in the pediatric population remains unclear since too few pediatric clinical trials were identified.<BR/>[4] The only recommendations for IV beta2-agonists use should be for those patients in whom inhaled therapy cannot be used, however there have been no tests of its efficacy in such situations.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-08-01 09:44:07 +0100" MODIFIED_BY="Toby J Lasserson">
<SUBSECTION>
<HEADING LEVEL="6">Population</HEADING>
<P>[1] The effectiveness of IV beta2-agonists in pediatric patients with severe acute asthma exacerbation's that present to the ED remains to be determined.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Interventions</HEADING>
<OL>
<LI>Future methodologically sound clinical trials could be justifiable to clarify whether IV beta2-agonists improve the initial bronchodilator response when given in addition to nebulised bronchodilator (beta2-agonists and anticholinergics) and corticosteroid therapy (intravenous, oral, or inhaled).</LI>
<LI>The evidence for subcutaneous routes of beta2-agonists (both selective and non-selective) must be formally evaluated via a systematic review.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcomes</HEADING>
<P>Future research on acute asthma must concentrate on well defined outcomes which may lead to more informative overviews in the future. More specifically the following areas must be refined:</P>
<OL>
<LI>Statistical planning and sample size calculations must be more carefully considered. Trials should be large enough to protect against type II error, and when multiple statistical tests are performed the increased risk of type I error should be addressed.</LI>
<LI>Complete reporting of PFT data in a systematic and standardised fashion would assist in further work (i.e. reporting of % predicted PEFR and changes in %PEFR).</LI>
<LI>The inherent variability of these PFTs, particularly in acute asthma, emphasizes the need for further research into alternative measures, particularly assessment of factors that are important to the patient.</LI>
<LI>Standardization and complete reporting of symptom data and universal descriptions of what defines a "clinical success".</LI>
<LI>Standardization and complete reporting of adverse reactions and side effects.</LI>
</OL>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The Canadian Association of Emergency Physicians (CAEP) has provided funding to carry out this review. In addition we would like to acknowledge the assistance provided by the Cochrane Airways Review Group staff (Steve Milan and Jane Dennis) in identifying the trials from the register and obtaining copies of the papers and the generous editorial support received from Prof. Paul Jones.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None. The authors are not involved in the primary research reported in this systematic review and have not represented the producers of these agents in the past.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Travers A: Initiated the review, wrote the protocol, performed searches, performed quality assessments, entered data and performed analysis, and primary author of review.<BR/>Jones AP: study selection, quality assessment, review of protocol.<BR/>Kelly KD: data extraction, entry and review.<BR/>Barker SJ: data extraction, entry and review.<BR/>Camargo CA Jr: Protocol development, methodological input, statistical support, manuscript review.<BR/>Rowe BH: Co-authored protocol, performed selection for inclusion and quality assessment, data extraction and data entry, manuscript review, conversion to RevMan 4, and assigned editor for ARG.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-01 09:48:01 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDIES MODIFIED="2008-08-01 09:48:01 +0100" MODIFIED_BY="Toby J Lasserson">
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bloomfield-1979" NAME="Bloomfield 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Bloomfield P, Carmichael J, Petrie GR, Jewell NP, Crompton GK.  Comparison of salbutamol given intravenously and by intermittent positive-pressure breathing in life-threatening asthma. BMJ 1979; 1:848-850.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bloomfield P, Carmichael J, Petrie GR, Jewell NP, Crompton GK</AU>
<TI>Comparison of salbutamol given intravenously and by intermittent positive-pressure breathing in life-threatening asthma</TI>
<SO>BMJ</SO>
<YR>1979</YR>
<VL>1</VL>
<PG>848-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Browne-1997" NAME="Browne 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Browne GJ, Penna AS, Phung X, Soo M.  Randomised trial of intravenous salbutamol in early management of acute asthma in children. Lancet 1997; 349:301-305.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Browne GJ, Penna AS, Phung X, Soo M</AU>
<TI>Randomised trial of intravenous salbutamol in early management of acute asthma in children</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>301-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheong-1988" NAME="Cheong 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Cheong B, Reynolds SR, Rajan G, Ward MJ. Intravenous B-agonist in severe acute asthma. BMJ 1988; 297:448-450.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheong B, Reynolds SR, Rajan G, Ward MJ</AU>
<TI>Intravenous B-agonist in severe acute asthma</TI>
<SO>BMJ</SO>
<YR>1988</YR>
<VL>297</VL>
<PG>448-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Femi_x002d_Pearse-1-1977" NAME="Femi-Pearse 1 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Femi-Pearse D, George WO, Ilechukwu ST, Elegbeleye OO, Afonja AO</AU>
<TI>Comparison of intravenous aminophylline and salbutamol in severe asthma</TI>
<SO>BMJ</SO>
<YR>1977</YR>
<VL>1</VL>
<PG>491</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Femi_x002d_Pearse-2-1977" NAME="Femi-Pearse 2 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Femi-Pearse D, George WO, Ilechukwu ST, Elegbeleye OO, Afonja AO</AU>
<TI>Comparison of intravenous aminophylline and salbutamol in severe asthma</TI>
<SO>BMJ</SO>
<YR>1977</YR>
<VL>1</VL>
<PG>491</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hambleton-1979" NAME="Hambleton 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hambleton G, Stone MJ</AU>
<TI>Comparison of IV salbutamol with IV aminophylline in the treatment of severe, acute asthma in childhood</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1979</YR>
<VL>54</VL>
<PG>391-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hussein-1986" NAME="Hussein 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hussein A, von der Hardt H, Muller W, Schell SM</AU>
<TI>Intravenous infusion of reproterol in the treatment of acute severe asthma in children</TI>
<SO>Monatsschrift fur Kinderheilkunde</SO>
<YR>1986</YR>
<VL>134</VL>
<PG>192-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1978" NAME="Johnson 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Johnson AJ, Spiro SG, Pidgeon J, Bateman S, Clarke SW.  Intravenous infusion of salbutamol in severe acute asthma. BMJ 1978; 1:1013-1015.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson AJ, Spiro SG, Pidgeon J, Bateman S, Clarke SW</AU>
<TI>Intravenous infusion of salbutamol in severe acute asthma</TI>
<SO>BMJ</SO>
<YR>1978</YR>
<VL>1</VL>
<PG>1013-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lawford-1978" NAME="Lawford 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Lawford P, Jones BJM, Milledge JS.  Comparison of intravenous and nebulised salbutamol in initial treatment of severe asthma. BMJ 1978; 1:84.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lawford P, Jones BJM, Milledge JS</AU>
<TI>Comparison of intravenous and nebulised salbutamol in initial treatment of severe asthma</TI>
<SO>BMJ</SO>
<YR>1978</YR>
<VL>1</VL>
<PG>84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salmeron-1994" NAME="Salmeron 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Salmeron S, Brochard L, Mal H, Tenaillon A, Henry-Amar M, Renon D, Duroux P, Simonneau G.  Nebulized versus intravenous albuterol in hypercapnic acute asthma: A multicenter, double-blind, randomized study.  Am J Respir Crit Care Med 1994; 149:1466-1470.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salmeron S, Brochard L, Mal H, Tenaillon A, Henry-Amar M, Renon D, et al</AU>
<TI>Nebulized versus intravenous albuterol in hypercapnic acute asthma: A multicenter, double-blind, randomized study</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1994</YR>
<VL>149</VL>
<PG>1466-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-1-1984" NAME="Sharma 1 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma TN, Gupta RB, Gupta PR, Purohit SD</AU>
<TI>Comparison of intravenous aminophylline, salbutamol, and terbutaline in acute asthma</TI>
<SO>Indian Journal of Chest Diseases &amp; Allied Sciences</SO>
<YR>1984</YR>
<VL>26</VL>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2-1984" NAME="Sharma 2 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharma TN, Gupta RB, Gupta PR, Purohit SD</AU>
<TI>Comparison of intravenous aminophylline, salbutamol, and terbutaline in acute asthma</TI>
<SO>Indian Journal of Chest Diseases &amp; Allied Sciences</SO>
<YR>1984</YR>
<VL>26</VL>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swedish-Society-1990" NAME="Swedish Society 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Swedish Society of Chest Medicine, Janson C, Boe J, Boman G, Larsson S, Mossberg B, Nyborg B, Oden A, Svedmyr N.  High-dose inhaled versus intravenous salbutamol combined with theophylline in severe acute asthma.  Eur Respir J 1990; 3:163-170.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swedish Society of Chest Medicine, Janson C, Boe J, Boman G, Larsson S, Mossberg B, et al</AU>
<TI>High-dose inhaled versus intravenous salbutamol combined with theophylline in severe acute asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>1990</YR>
<VL>3</VL>
<PG>163-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tribe-1976" NAME="Tribe 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Tribe AE, Wong RM, Robinson JS.  A controlled trial of intravenous salbutamol and aminophylline in acute asthma.  Med J Aust 1976; 2:749-752.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tribe AE, Wong RM, Robinson JS</AU>
<TI>A controlled trial of intravenous salbutamol and aminophylline in acute asthma</TI>
<SO>Medical Journal of Australia</SO>
<YR>1976</YR>
<VL>2</VL>
<PG>749-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Renterghem-1987" NAME="Van Renterghem 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Van Renterghem D, Lamont H, Elinck W, Pauwels R, Van Der Straeten M.  Intravenous versus nebulized terbutaline in patients with acute asthma: a double-blind study.  Annals of Allergy 1987; 59:313-316.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Renterghem D, Lamont H, Elinck W, Pauwels R, Van Der Straeten M</AU>
<TI>Intravenous versus nebulized terbutaline in patients with acute asthma: a double-blind study</TI>
<SO>Annals of Allergy</SO>
<YR>1987</YR>
<VL>59</VL>
<PG>313-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-1975" NAME="Williams 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Williams SJ, Winner SJ, Clark TJH.  Comparison of inhaled and intravenous terbutaline in acute severe asthma.  Thorax 1981; 36:629-631.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams SJ, Winner SJ, Clark TJH</AU>
<TI>Comparison of inhaled and intravenous terbutaline in acute severe asthma</TI>
<SO>Thorax</SO>
<YR>1981</YR>
<VL>36</VL>
<PG>629-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-1981" NAME="Williams 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Williams SJ, Parrish RW, Seaton A.  Comparison of intravenous aminophylline and salbutamol in severe asthma.  BMJ 1975; 4:685.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams SJ, Parrish RW, Seaton A</AU>
<TI>Comparison of intravenous aminophylline and salbutamol in severe asthma</TI>
<SO>BMJ</SO>
<YR>1975</YR>
<VL>4</VL>
<PG>685</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-08-01 09:48:01 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-1978" NAME="Anonymous 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Anonymous. Intravenous versus inhaled salbutamol.  Lancet 1978; 1:80.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Intravenous versus inhaled salbutamol</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>1</VL>
<PG>80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnaud-1977" NAME="Arnaud 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Arnaud A, Dugue P, Orehek J, et al. Treatment of acute asthma. Comparison of the effectiveness of corticosteroids and a combination of corticosteroids and an adrenergic beta-stimulant.  La Nouvell Presse Medicale 1977: 6:4183-4186.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnaud A, Dugue P, Orehek J, et al</AU>
<TI>Treatment of acute asthma. Comparison of the effectiveness of corticosteroids and a combination of corticosteroids and an adrenergic beta-stimulant</TI>
<SO>Nouvelle Presse Medicale</SO>
<YR>1977</YR>
<VL>6</VL>
<PG>4183-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beswick-1975" NAME="Beswick 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Beswick K, Davies J, Davey AJ.  A comparison of intravenous aminophylline and salbutamol in the treatment of severe bronchospasm.  The Practitioner 1975; 214:561-566.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beswick K, Davies J, Davey AJ</AU>
<TI>A comparison of intravenous aminophylline and salbutamol in the treatment of severe bronchospasm</TI>
<SO>The Practitioner</SO>
<YR>1975</YR>
<VL>214</VL>
<PG>561-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blumenthal-1979" NAME="Blumenthal 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blumenthal I, Tormey W</AU>
<TI>Comparison of IV salbutamol with IV aminophylline in severe acute asthma</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1979</YR>
<VL>54</VL>
<PG>983-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boe-1985" NAME="Boe 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Boe J, Carlsson LG, Hetta L, Karlson B, Ljungholm K.  Acute asthma - plasma levels and effect of terbutaline i.v. injection.  Eur J Respir Dis 1985; 67:261-268.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boe J, Carlsson LG, Hetta L, Karlson B, Ljungholm K</AU>
<TI>Acute asthma - plasma levels and effect of terbutaline i.v. injection</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1985</YR>
<VL>67</VL>
<PG>261-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bohn-1984" NAME="Bohn 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Bohn D, Kalloghlian A, Jenkins J, Edmonds J, Barker G.  Intravenous salbutamol in the treatment of status asthmaticus in children.  Crit Care Med 1984; 12:892-896.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bohn D, Kalloghlian A, Jenkins J, Edmonds J, Barker G</AU>
<TI>Intravenous salbutamol in the treatment of status asthmaticus in children</TI>
<SO>Critical Care Medicine</SO>
<YR>1984</YR>
<VL>12</VL>
<PG>892-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruguerolle-1991" NAME="Bruguerolle 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruguerolle B, Philip-Joet F, Lagier F, et al</AU>
<TI>Unequal day-night terbutaline IV dosing in acute severe asthma: effect on nocturnal patency, heart rate, and arterial pressure</TI>
<SO>Chronobiology International</SO>
<YR>1991</YR>
<VL>8</VL>
<PG>194-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crompton-1990" NAME="Crompton 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Crompton G. Nebulized or intravenous beta-adrenoceptor agonist therapy i acute asthma. Eur Respi J 1990; 3: 125-126.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crompton G</AU>
<TI>Nebulized or intravenous beta-adrenoceptor agonist therapy in acute asthma</TI>
<SO>European Respiratory Journal</SO>
<YR>1990</YR>
<VL>3</VL>
<PG>125-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Downes-1973" MODIFIED="2008-08-01 09:48:01 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Downes 1973" YEAR="1973">
<REFERENCE MODIFIED="2008-08-01 09:48:01 +0100" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Downes J, Wood D, Harwood I</AU>
<TI>Intravenous isoproterenol infusion in children with severe hypercapnia due to status asthmaticus</TI>
<SO>Critical Care Medicine</SO>
<YR>1973</YR>
<VL>1</VL>
<NO>2</NO>
<PG>63-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edmunds-1981" NAME="Edmunds 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Edmunds AT, Godfrey S.  Cardiovascular response during severe acute asthma and its treatment in children.  Thorax 1981; 36:534-540.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edmunds AT, Godfrey S</AU>
<TI>Cardiovascular response during severe acute asthma and its treatment in children</TI>
<SO>Thorax</SO>
<YR>1981</YR>
<VL>36</VL>
<PG>534-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1980" NAME="Evans 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Evans WV, Monie J, Crimmins J, Seaton A.  Aminophylline, salbutamol and combined intravenous infusions in acute severe asthma.  Br J Dis Chest 1980; 74:385-389.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans WV, Monie J, Crimmins J, Seaton A</AU>
<TI>Aminophylline, salbutamol and combined intravenous infusions in acute severe asthma</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1980</YR>
<VL>74</VL>
<PG>385-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitchett-1975" NAME="Fitchett 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Fitchett DH, McNicol MW, Riordan JF.  Intravenous salbutamol in management of status asthmaticus.  BMJ 1975; 1:53-55.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitchett DH, McNicol MW, Riordan JF</AU>
<TI>Intravenous salbutamol in management of status asthmaticus</TI>
<SO>BMJ</SO>
<YR>1975</YR>
<VL>1</VL>
<PG>53-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grant-1976" NAME="Grant 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Grant I. Effect of intravenous injection of salbutamol in asthma. Brit J Clin Pharmac 1976; 3:509-510.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grant I</AU>
<TI>Effect of intravenous injection of salbutamol in asthma</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1976</YR>
<VL>3</VL>
<PG>509-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greif-1985" NAME="Greif 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Greif J, Markovitz L, Topilsky M.  Comparison of intravenous salbutamol (albuterol) and aminophylline in the treatment of acute asthmatic attacks.  Annals of Allergy 1985; 55:504-506.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greif J, Markovitz L, Topilsky M</AU>
<TI>Comparison of intravenous salbutamol (albuterol) and aminophylline in the treatment of acute asthmatic attacks</TI>
<SO>Annals of Allergy</SO>
<YR>1985</YR>
<VL>55</VL>
<PG>504-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herman-1983" NAME="Herman 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Herman JJ, Noah ZL, Moody RR.  Use of intravenous isoproterenol for status asthmaticus in children.  Crit Care Med 1983; 11:716-720.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herman JJ, Noah ZL, Moody RR</AU>
<TI>Use of intravenous isoproterenol for status asthmaticus in children</TI>
<SO>Critical Care Medicine</SO>
<YR>1983</YR>
<VL>11</VL>
<PG>716-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hetzel-1976" NAME="Hetzel 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Hetzel MR, Clark TJH.  Comparison of intravenous and aerosol salbutamol.  BMJ 1976; :919.&lt;br&gt;Hetzel MR. Clark TJ. Comparison of intravenous and aerosol salbutamol. [Journal Article] British Medical Journal. 2(6041):919, 1976 Oct 16. UI: 974663&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hetzel MR, Clark TJH</AU>
<TI>Comparison of intravenous and aerosol salbutamol</TI>
<SO>BMJ</SO>
<YR>1976</YR>
<VL>2</VL>
<NO>6014</NO>
<PG>919</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirsch-1979" NAME="Hirsch 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Hirsch SR.  Intravenous therapy with terbutaline.  Chest 1979; 75:648.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch SR</AU>
<TI>Intravenous therapy with terbutaline</TI>
<SO>Chest</SO>
<YR>1979</YR>
<VL>75</VL>
<PG>648</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iodice-1980" NAME="Iodice 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Iodice F, Rufolo L, Piscione F, De Michele G.  Hemodynamic and ventilatory effects of intravenous salbutamol in patients affected by cold.  Respiration 1980; 40:272-277.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iodice F, Rufolo L, Piscione F, De Michele G</AU>
<TI>Hemodynamic and ventilatory effects of intravenous salbutamol in patients affected by cold</TI>
<SO>Respiration</SO>
<YR>1980</YR>
<VL>40</VL>
<PG>272-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janson-1992" NAME="Janson 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Janson C, Boman D Intravenous theophylline after beta-agonist treatment in severe acute asthma.  Effect on patients who are not treated with theophylline.  Ups J Med Sci 1992; 97:149-155.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janson C, Boman D</AU>
<TI>Intravenous theophylline after beta 2-agonist treatment in severe acute asthma. Effect on patients who are not pre-treated with theophylline</TI>
<SO>Upsala Journal of Medical Sciences</SO>
<YR>1992</YR>
<VL>97</VL>
<PG>149-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marlin-1975" NAME="Marlin 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Marlin G, Turner P. Intravenous treatment with rimiterol and salbutamol. Brit Med J 1975; 2:715-719.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marlin G, Turner P</AU>
<TI>Intravenous treatment with rimiterol and salbutamol</TI>
<SO>BMJ</SO>
<YR>1975</YR>
<VL>2</VL>
<PG>715-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-May-1975" NAME="May 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;May CS, Paterson JW, Spiro SG, Johnson AJ.  Intravenous infusion of salbutamol in the treatment of asthma.  Br J Clin Pharmac 1975; 2:503-508.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>May CS, Paterson JW, Spiro SG, Johnson AJ</AU>
<TI>Intravenous infusion of salbutamol in the treatment of asthma</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1975</YR>
<VL>2</VL>
<PG>503-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nogrady-1977" NAME="Nogrady 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Nogrady SG, Hartley JPR, Seaton A.  Metabolic effects of intravenous salbutamol in the course of acute asthma.  Thorax 1977; 32:559-562.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nogrady SG, Hartley JPR, Seaton A</AU>
<TI>Metabolic effects of intravenous salbutamol in the course of acute asthma</TI>
<SO>Thorax</SO>
<YR>1977</YR>
<VL>32</VL>
<PG>559-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noseda-1989" NAME="Noseda 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Noseda A, Yernault JC.  Sympathomimetics in acute severe asthma: inhaled or parenteral, nebulizer or spacer?  Eur Respir J 1989; 2:377-382.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noseda A, Yernault JC</AU>
<TI>Sympathomimetics in acute severe asthma: inhaled or parenteral, nebulizer or spacer?</TI>
<SO>European Respiratory Journal</SO>
<YR>1989</YR>
<VL>2</VL>
<PG>377-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Connell-1990" NAME="O'Connell 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;O'Connell MB, Iber C.  Continuous intravenous terbutaline infusions for adult patients with status asthmaticus.  Annals of Allergy 1990; 64:213-218.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Connell MB, Iber C</AU>
<TI>Continuous intravenous terbutaline infusions for adult patients with status asthmaticus</TI>
<SO>Annals of Allergy</SO>
<YR>1990</YR>
<VL>64</VL>
<PG>213-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parry-1976" NAME="Parry 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parry L, Martorano, Cotton E</AU>
<TI>Management of life-threatening asthma with intravenous isoproterenol infusions</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1976</YR>
<VL>130</VL>
<PG>39-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pierce-1981" NAME="Pierce 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Pierce RJ, Payne CR, Williams SJ, Denison DM, Clark TJH.  Comparison of intravenous and inhaled terbutaline in the treatment of asthma.  Chest 1981; 79:506-511.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pierce RJ, Payne CR, Williams SJ, Denison DM, Clark TJH</AU>
<TI>Comparison of intravenous and inhaled terbutaline in the treatment of asthma</TI>
<SO>Chest</SO>
<YR>1981</YR>
<VL>79</VL>
<PG>506-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salmeron-1995" NAME="Salmeron 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Salmeron S, Ellrodt A, Taravella O.  Sympathomimetics in severe acute asthma.  Lancet 1995; 346:257.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salmeron S, Ellrodt A, Taravella O</AU>
<TI>Sympathomimetics in severe acute asthma</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>346</VL>
<PG>257</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiavi-1987" NAME="Schiavi 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Schiavi E. Efecto agudo salbutamol intravenosos en et astado de mal asmatico. Medicina 1987; 47: 39-44.&lt;br&gt;Schiavi EA. [] [Journal Article] Medicina. 47(1):39-44, 1987.  UI: 3613968&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiavi E</AU>
<TI>Acute effect of intravenous salbutamol in status asthmaticus. Article in Spanish</TI>
<TO>Efecto agudo salbutamol intravenosos en et astado de mal asmatico</TO>
<SO>Medicina</SO>
<YR>1987</YR>
<VL>47</VL>
<PG>39-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1986" NAME="Smith 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Smith SR, Kendall MJ.  Potentiation of the adverse effects of intravenous terbutaline by oral theophylline.  Br J Clin Pharmac 1986; 21:451-453.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith SR, Kendall MJ</AU>
<TI>Potentiation of the adverse effects of intravenous terbutaline by oral theophylline</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1986</YR>
<VL>21</VL>
<PG>451-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spiro-1975" NAME="Spiro 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Spiro SG, Johnson AJ, May CS, Paterson JW.  Effect of intravenous injection of salbutamol in asthma.  Br J Clin Pharmac 1975; 2:495-501.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spiro SG, Johnson AJ, May CS, Paterson JW</AU>
<TI>Effect of intravenous injection of salbutamol in asthma</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1975</YR>
<VL>2</VL>
<PG>495-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subias-1989" NAME="Subias 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Escribano Subias J. Sanz Manrique N. Morales Hidalgo V. Clofent Vilaplana R. Iglesias Berenguer J. Roqueta Mas J. Eseverri Asin JL. [Treatment of status asthmaticus. Experience of intravenous beta-adrenergic bronchodilator therapy in 71 cases]. [Spanish] [Journal Article] Anales Espanoles de Pediatria. 31(5):435-9, 1989 Nov.  UI: 2694871&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subias J, Manrique N, Hidalgo V</AU>
<TI>Status asthmaticus treatment: beta-agonist therapy experience in 71 cases</TI>
<SO>Anales Espanoles de Pediatria</SO>
<YR>1989</YR>
<VL>31</VL>
<PG>435-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teoh-1979" NAME="Teoh 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Teoh P. Clinical evaluation of intravenous hexoprenaline in bronchial asthma. Annals Academy of Medicine 1979; 8:144-147.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teoh P</AU>
<TI>Clinical evaluation of intravenous hexoprenaline in bronchial asthma</TI>
<SO>Annals Academy of Medicine</SO>
<YR>1979</YR>
<VL>8</VL>
<PG>144-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thiringer-1976" NAME="Thiringer 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Thiringer G, Svedmyr N.  Comparison of infused and inhaled terbutaline in patients with asthma.  Scand J Resp Dis 1976; 57:17-24.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thiringer G, Svedmyr N</AU>
<TI>Comparison of infused and inhaled terbutaline in patients with asthma</TI>
<SO>Scandinavian Journal of Respiratory Diseases</SO>
<YR>1976</YR>
<VL>57</VL>
<PG>17-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ting-1991" NAME="Ting 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Ting CK. Liao MH. A comparative study of epinephrine injection and beta 2-agonist inhalation in the treatment of childhood asthma. [Chinese] [Clinical Trial. Journal Article. Randomized Controlled Trial] Chung-Hua Min Kuo Hsiao Erh Ko i Hsueh Hui Tsa Chih. 32(6):372-81, 1991 Nov-Dec.  UI: 1688066&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ting C</AU>
<TI>A comparative study of epinephrine injection and beta-agonist inhalation in the treatment of childhood asthma</TI>
<SO>Chung-Hua Min Kuo Hsiao Erh Ko i Hsueh Hui Tsa Chih</SO>
<YR>1991</YR>
<VL>32</VL>
<PG>372-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tirot-1992" NAME="Tirot 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Tirot P, Bouachour G, Varache N, et al. The use of intravenous adrenaline in acute severe asthma. Rev Mal Resp 1992; 9:319-323.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tirot P, Bouachour G, Varache N, et al</AU>
<TI>The use of intravenous adrenaline in acute severe asthma</TI>
<SO>Revue des Maladies Respiratoires</SO>
<YR>1992</YR>
<VL>9</VL>
<PG>319-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tripathi-1989" NAME="Tripathi 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Tripathi S. management of acute bronchial asthma -  intravenous terbutaline or aminophylline. J Ind Med Assoc 1989; 87:75-76.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tripathi S</AU>
<TI>Management of acute bronchial asthma--intravenous terbutaline or aminophylline?</TI>
<SO>Journal of the Indian Medical Association</SO>
<YR>1989</YR>
<VL>87</VL>
<PG>75-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-1977" NAME="Williams 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Williams S, Seaton A.  Intravenous or inhaled salbutamol in severe acute asthma?  Thorax 1977; 32:555-558.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams S, Seaton A</AU>
<TI>Intravenous or inhaled salbutamol in severe acute asthma?</TI>
<SO>Thorax</SO>
<YR>1977</YR>
<VL>32</VL>
<PG>555-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wood-1972" NAME="Wood 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wood D, Downes J, Scheinkopf H, et al</AU>
<TI>Intravenous isoproterenol in the management or respiratory arrest in childhood status asthmaticus</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1972</YR>
<VL>50</VL>
<PG>75-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wood-1973" NAME="Wood 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wood D, Downes J</AU>
<TI>Intravenous isoproterenol in the treatment of respiratory failure in childhood status asthmaticus</TI>
<SO>Annals of Allergy</SO>
<YR>1973</YR>
<VL>31</VL>
<PG>607-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-01 09:41:27 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-01 09:41:27 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-ATS-1962" MODIFIED="2008-08-01 09:41:27 +0100" MODIFIED_BY="Toby J Lasserson" NAME="ATS 1962" TYPE="JOURNAL_ARTICLE">
<AU>American Thoracic Society</AU>
<TI>Chronic bronchitis, asthma, and pulmonary emphysema: a statement by the Committee on diagnostic standards for non-tuberculosis respiratory disease.</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1962</YR>
<VL>85</VL>
<PG>762-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beveridge-1996" MODIFIED="2008-08-01 09:41:27 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Beveridge 1996" TYPE="JOURNAL_ARTICLE">
<AU>Beveridge RC, Grunfeld AF, Hodder RV, Verbeek PR</AU>
<TI>Guidelines for the emergency management of asthma in adults</TI>
<SO>Canadian Medical Association Journal (CMAJ)</SO>
<YR>1996</YR>
<VL>155</VL>
<PG>25-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ernst-1996" MODIFIED="2008-08-01 09:41:27 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Ernst 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ernst P, Fitzgerald J, Spier S</AU>
<TI>Canadian Asthma Consensus Conference: summary of recommendations</TI>
<SO>Canadian Respiratory Journal</SO>
<YR>1996</YR>
<VL>3</VL>
<PG>89-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-08-01 09:40:41 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D</AU>
<TI>Assessing the quality or reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipworth-1997" MODIFIED="2008-08-01 09:41:27 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Lipworth 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lipworth BJ</AU>
<TI>Treatment of acute asthma</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>sii18-sii23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1999" MODIFIED="2008-08-01 09:40:41 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Mulrow 1999" TYPE="OTHER">
<AU>Mulrow C, Oxman A</AU>
<TI>Cochrane Collaboration Handbook</TI>
<SO>The Cochrane Library</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NAEPP-1997" MODIFIED="2008-08-01 09:41:27 +0100" MODIFIED_BY="Toby J Lasserson" NAME="NAEPP 1997" TYPE="JOURNAL_ARTICLE">
<AU>National Asthma Education Program Expert Panel Report 2</AU>
<TI>Guidelines for the Diagnosis and Management of Asthma</TI>
<SO>Bethesda: NIH</SO>
<YR>1997</YR>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-08-01 09:47:55 +0100" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-01 09:46:39 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bloomfield-1979">
<CHAR_METHODS>
<P>Randomisation: yes (of order of treatment)<BR/>Blinding: double-blind<BR/>Number excluded: no details<BR/>Withdrawals: 2 due to worsening clinical condition<BR/>Baseline characteristics: PEFR 103 (&lt; 20% predicted); HR 138; RR 27.5; PaO2 87 (38, 124); pulsus paradoxus 33.8<BR/>Jadad score: "strong", score &gt;/= 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Edinburgh, Scotland<BR/>Participants: initially 19 (2 had contaminated neb Rx and were excluded), 20 eligible (of the 17 pts, 1 presented twice, and 1 thrice), 17-54 yrs (mean 27.35)<BR/>Asthma definition and severity: all patients with severe acute asthma with HR &gt; 120 beats/min and PEFR &lt; 20% of predicted<BR/>Exclusion criteria: none stated<BR/>Inhaled corticosteroid use: 12 patients<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Crossover design one hour apart<BR/>Standard care: O2 NPV 35 %, hydrocortisone 500 mg iv<BR/>Treatment group: salbutamol 5mg IPPB at 0 min or at 60 min vs. salbutamol 500 ug iv over 3 minutes at 0 min or at 60 min <BR/>Placebo: saline neb or injection<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PFTs: PEFR iv pos 34, pos 25, pos 21, pos 24, pos 54; neb pos 20, pos 29, pos 26, pos 22, pos 74; summary PEFR pos 74.1 at 120 min (iv then neb)<BR/>Timing: 15, 30, 45, 60, 120 min<BR/>Admissions:<BR/>Side effects 4 tremor, 2 palp<BR/>Complications:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Browne-1997">
<CHAR_METHODS>
<P>Randomization: yes (table of random numbers)<BR/>Blinding: double-blind<BR/>Number excluded: 13<BR/>Withdrawals: none<BR/>Baseline characteristics: HR 127.8 (15.4 ) iv, 146.2 (13.6) neb; RR 38.9 (11.9) iv, 45.8 (9.9) neb; glucose 7.5 (2.7) iv, 8.5 (3.1) neb; potassium 3.9 (0.5) iv, 4.2 (0.6) neb; pulm index 12 iv, 15 neb; acc muscle use 12 iv, 15 neb; SOB 12 iv, 13 neb; wheeze 13 iv, 14 neb; fatigue 7 iv, 9 neb<BR/>Jadad score: "strong", score &gt; 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Westmead, Australia<BR/>Participants: initially 50, 37 eligible, 29 final (8 gave no consent), 1-12 yrs (mean 8.4 iv, 6.3 neb); males 7 iv, 12 neb; females 7 iv, 3 neb; height 1.3m (0.2) iv, 1.2m (0.2) neb; weight 29.2 kg (10.1) iv, 22.5 kg (8.1) neb<BR/>Asthma definition and severity: severe acute asthma as per NAAC guidelines<BR/>Exclusion criteria: mild, moderate or life-threatening asthma, CHD, SVT, respiratory illness, DM, &lt;10kg, &gt;50kg, &lt;12mos, &gt;12yrs, max iv dose already<BR/>Inhaled corticosteroid use: no details<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Standard care: Coincident with iv drugs, O2 NPV 30%, continuous salbutamol 2.5 mg ( &lt; 2 yrs ) or 5 mg ( &gt; 2 yrs ), hydrocortisone 5 mg/kg iv, then from 2 hrs onwards continuous salbutamol, then q30 min, q60 min, q2h, q3h, q4h prn<BR/>Treatment group: placebo vs. salbutamol iv 15 ug/kg over 10 min at 0 min<BR/>Placebo: saline<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PFTs: not done<BR/>Timing: not done<BR/>Admissions: all patients admitted to high-dependency ward<BR/>Side effects: higher proportion with tremor at 2 hr (specifics unknown)<BR/>Complications:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Run in period of 30 min where pts given salb neb of 2.5 or 5 mg<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cheong-1988">
<CHAR_METHODS>
<P>Randomization: yes (unknown, sealed envelope)<BR/>Blinding: no<BR/>Number excluded: no details<BR/>Withdrawals: 5 (2 iv due to side effects and 3 neb due to non-response)<BR/>Baseline characteristics: HR 114 (SD 14) iv, 110 (SD 14) neb; PaO2 8.8 (1.1) kpa iv, 9.1 (1.2 ) kpa neb; PaCO2 4.9 (1.0) kpa iv, 4.7 (0.7) kpa neb; PEFR 91 (37.2) iv, 111 (53.4) neb (predicted PEFR 20.4 (6.9) iv, 24 (9.1) neb)<BR/>Jadad score: "strong", score &gt;/= 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Penarth, South Glamorgan<BR/>Participants: 76 eligible, 71 final (5 removed b/c adverse effects, or non-response to Rx); 16-70 yrs (mean 37 yrs (16-69) iv, 35 yrs (16-66) neb); males 26 iv, 23 neb; females 11 iv, 12 neb<BR/>Asthma definition and severity: initially PEF &lt; 20% predicted, run in phase selecting those with expected PEFR &lt; 50% 30 min after first nebulized treatment of salbutamol<BR/>Exclusion criteria: history of CV disease, prehospital steroid use, previous iv bronchodilator use<BR/>Inhaled corticosteroid use: no details<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Standard care: For first 30 min O2 NP35%, salbutamol 5 mg neb X 1, hydrocortisone 200 mg iv<BR/>Treatment group: salbutamol 5 mg neb at 30 min and at 120 min vs. salbutamol iv infusion 12.5 ug/min for four hrs at 30 min<BR/>Placebo: ?</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PFTs: % PEFR response iv 6.3 (SD 5.9), 13.2 (SD 12.4), 17.3 (SD 15.6), 25.2 (SD 19.9); neb 6.3 (SD 8.5), 10.9 (SD 13.9), 10.6 (SD 13.3), 14.3 (SD 15.9)<BR/>Timing: 30, 60, 150, 240 min<BR/>Admissions:<BR/>Side effects: 1 HA &amp; palp, 1 tremor and palp<BR/>Complications:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Iv meds given at 30 min after run-in phase ( which produced a 6.3% response in PEFR ), hence times are 'off' by +30 min<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Femi_x002d_Pearse-1-1977">
<CHAR_METHODS>
<P>randomised, parallel protocol<BR/>Jadad Score: "weak", score &lt; 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>i.v. salbutamol vs. i.v. aminophylline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>delta VS, delta PEFR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Femi_x002d_Pearse-2-1977">
<CHAR_METHODS>
<P>randomised, parallel<BR/>Jadad Score: "weak", score &lt; 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>i.v. salbutamol vs. i.v. aminophylline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>delta VS, delta PEFR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hambleton-1979">
<CHAR_METHODS>
<P>randomized, parallel protocol<BR/>Jadad Score: "weak", score &lt; 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>intravenous salbutamol vs. intravenous aminophylline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>delta clinical scores, VS, ASE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hussein-1986">
<CHAR_METHODS>
<P>Randomized, parallel trial<BR/>Jadad Score: "weak", score &lt; 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Children. N = 18</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>IV repreoterol vs. inhaled reproterol</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>VS, ABGs, %pred PEFR, clinical score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Johnson-1978">
<CHAR_METHODS>
<P>Randomization: yes (mentioned in passing only)<BR/>Blinding: no<BR/>Number excluded: 23<BR/>Withdrawals: 8 (6 from iv salb because unsatisfactory response starting at 8 to 32 hrs and 2 from comparison at 24 h due to no response)<BR/>Baseline characteristics: HR 109 (sd 4) salb, 107 (sd 5) amino, 110 (sd 3) cont; BP 134 (sd 5) / 81 (sd 2) salb, 141 (sd 6) / 83 (sd 3) amino, 137 (sd 3) / 83 (sd 2) cont; PaO2 8.3 (sd 0.3) salb, 7.5 (sd 0.7) amino, 8.0 (sd 0.4) cont; PaCO2 5.1 (sd 0.2) salb, 5.0 (sd 0.1) amino, 5.2 (sd 0.3) cont; pH 7.4 (sd 0.01) salb, 7.38 (sd 0.01), 7.4 (sd 0.01) cont; PEFR/FEV 98 (sd 8 ) / 0.6 (sd 0.1) salb, 92 (sd 9) / 1.1 (sd 0.2) amino, 108 (sd 10) / 1.0 (sd 0.1) cont<BR/>Jadad score: "weak", score &lt; 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: London, England<BR/>Participants: initially 62, 39 final (23 improved with run in Rx); 16- 65 yrs (mean 36.2 salb, 41.9 amino, 36.7 control); males 9 salb, 4 amino, 11 cont; females 11 salb, 15 amino, 12 cont; height 168.2 cm (SD 1.9) salb, 162.6 cm (SD 1.7) amino, 167.9 cm (SD 1.8) cont; weight 63.9 kg (SD 1.5) salb, 60.8 kg (SD 2.6) amino, 63.5 kg (SD 1.5) cont<BR/>Asthma definition and severity: PEFR&lt;150 (not mentioned, abstracted from article instead), run in phase for about 45 min of aminophylline/ neb salbutamol/ hydrocortisone, RCT<BR/>Exclusion criteria: presence of CV or renal disease, improvement with run in phase<BR/>Inhaled corticosteroid use: 30 equally distributed<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Run in phase with inclusion and rand at 75 min, consecutive pts, parallel cohort of drug A vs. drug B, crossover possible at MD discretion, compared to 'control' group<BR/>Standard care: For first 75 min O2 NPV 35%, aminophylline 5 mg/kg iv load, hydrocortisone 200 mg iv, prednisone 40 mg po qd, salbutamol 5 mg IPPB q6h, physioTx <BR/>Treatment group: aminophylline infusion 1 mg/min at 75 min and 'control group' of inhaled salbutamol vs. salbutamol iv infusion at 10 ug/min at 75 min<BR/>Placebo: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PFTs: PEFR/% PEFR Response/FEV salb 146 (sd10)/ FVC 2 (sd 0.2)/ 0.8 (sd 0.1), 133.3 / ? / 0.79, 148 / ? / 1.0; cont 145 (sd 15)/ FVC 1.9 (sd 0.2)/ 0.9 (sd 0.1), 150 / ? / 0.93, 170.8 / ? / 1.07 <BR/>Timing: 15, 60, 360 min<BR/>Admissions:<BR/>Side effects: no details<BR/>Complications:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lawford-1978">
<CHAR_METHODS>
<P>Randomization: yes (mentioned in passing, mentioned as numbered ampules &amp; bottles)<BR/>Blinding: double-blind<BR/>Number excluded: no details<BR/>Withdrawals: 2<BR/>Baseline characteristics: HR 119 (sd 21) iv, 115 (sd 30) neb; PaO2 12.3 (sd 2.7) iv, 11.4 (sd 2.4) neb; PaCO2 4.7 (sd 0.5) iv, 5.6 (sd 1.6) neb; PEFR/FEV 86 (sd 26) / 0.68 (sd 0.24) iv, 82 (sd 23) / 0.52 (sd 0.15) neb<BR/>Jadad score: "strong", score &gt;/= 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Harrow, Middlesex, England<BR/>Participants: 16 eligible, 14 final (2 removed because of side effects to iv meds), 15-65 yrs (mean ?)<BR/>Asthma definition and severity: unresponsive to hospital meds, no steroids in previous 6 hrs, no recent changes in oral steroid dose, PEF &lt; 120L <BR/>Exclusion criteria: no details<BR/>Inhaled corticosteroid use: no details<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Standard care: O2 40% NPV, hydrocortisone 250 mg iv<BR/>Treatment group: salb 10 mg NEB at 0 min lasting for 45 min vs. salb iv infusion 20 ug/min at 0 min lasting for 45 min<BR/>Placebo: saline<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PFTs: PEFR/FEV iv pos 38 (sd 68)/ 0.44 (sd 0.35); neb pos 51 (sd 56)/ 0.21 (sd 0.13)<BR/>Timing: 45 min<BR/>Admissions:<BR/>Side effects: 5 of 9 had undesirable SE (2 withdrew, 2 tremor, 1 palp)<BR/>Complications:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Salmeron-1994">
<CHAR_METHODS>
<P>Randomization: yes (method not mentioned)<BR/>Blinding: double-blind<BR/>Number excluded: no details<BR/>Withdrawals: 6 (5 iv and 1 neb due to no improvement)<BR/>Baseline characteristics: HR 115 (sd 19) iv, 118 (sd 19) neb; BP 153 (sd 28) / 88 (sd 17) iv, 152 (sd 28) / 89 (sd 14) neb; clinical index 10.2 (sd 2.3) iv, 10.0 (sd 2.1) neb; PaCO2 50 (sd 11) iv, 51 (sd 8) neb; PEFR 78 (sd 76) iv, 59 (sd 61) neb<BR/>Jadad score: "strong", score &gt;/=3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: multicenters in France<BR/>Participants: 48 eligible, 47 final (one patient was included twice in same group); 16-75 yrs (mean39 (sd 13) iv, 41 (sd 17) neb); males 17 iv, 10 neb; females 8 iv, 12 neb<BR/>Asthma definition and severity: definition of the American Thoracic Society, severe acute asthma with hypercapnea and severe clinical symptoms, including breathlessness or wheeze refractory to normal meds, PEFR &lt; 150 l/min, PaCO2 &gt;= 40<BR/>Exclusion criteria: COPD, LV Failure, use of nonbeta-agonist MDI within the past 60 min<BR/>Inhaled corticosteroid use: 20 (oral: 5 of 22 neb, 6 of 23 iv), (inhaled 9 overall)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Parallel protocol of iv vs. neb albuterol, review for continued Rx at 60 min<BR/>Standard care: O2 30% NPV, hydrocortisone 200 mg iv, crystalloid bolus<BR/>Treatment group: albuterol 10 mg RA neb (two 5 mg nebs over 15 min for one hour), then if successful continue Rx 5 mg NEB q2h for 7 h vs. albuterol iv infusion of 8.3 ug/min for 60 min (total 500 ug) at 0 min lasting for 1 hr, then if successful continue Rx 500 ug/hr for 7h<BR/>Placebo: saline<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PFTs: PEFR iv pos 42 (sd 66), 240 (sd 115); neb pos 107 (sd 94)pos 254 (sd 90) <BR/>Timing: 60, 480 min<BR/>Admissions:<BR/>Side effects: no details<BR/>Complications: 2 intubated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author correspondence:<BR/>"Successful Rx" presence of at least 2 items at 60 min, [1] delta CI &gt;= 3, [2] delta PaCO2 &gt;= neg3, [3] delta PEF &gt;= pos50</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sharma-1-1984">
<CHAR_METHODS>
<P>randmoized, parallel protocol<BR/>Jadad Score: "weak", score &lt; 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Adults. N = 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>intravenous salbutamol vs. i.v. aminophylline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>delta FEV1, delta MMFR, ASE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sharma-2-1984">
<CHAR_METHODS>
<P>randomized, parallel protocol<BR/>Jadad Score: "weak", score &lt; 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>i.v terbutaline vs. i.v. aminophylline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>delta FEV1, delta MMFR, ASE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Swedish-Society-1990">
<CHAR_METHODS>
<P>Randomization: yes (blocked randomization in sets of four)<BR/>Blinding: no<BR/>Number excluded: 2<BR/>Withdrawals: no details<BR/>Baseline characteristics: HR 111 (sd 10) iv, 112 (sd 9) neb; BP 140 (sd 21) / 88 (sd 12) iv, 145 (sd 20) / 87 (sd 11) neb; PEFR 166 (sd 70) iv, 170 (sd 47) neb (predicted 31 (sd 8) iv, 33 (sd 9) neb)<BR/>Jadad score: "weak", score &lt; 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: multicenters in Sweden<BR/>Participants: initially 178 eligible, 176 final (2 excluded because of incomplete records, 89 iv, 87 neb); mean 55 yrs (sd 13) iv, 58 yrs (sd 12) neb; males 50 iv, 43 neb; females 39 iv, 44 neb<BR/>Asthma definition and severity: rapid onset, HR &gt;= 100, predPEF &lt;= 50%, Hx of variable SOB &amp; wheezing above and one of the following: [1] diurnal variation of PEF of &gt;= 25%, [2] 15% reversible airway obstruction by beta-agonist, [3] bronchial hyperreactivity by methacholine/histamine<BR/>Exclusion criteria: extremely severe b/c pred PEF&lt; 15%, known COPD, severe HTN or heart dz, &gt; 75 yrs, those on beta blockers<BR/>Inhaled corticosteroid use: iv (62% inhaled, 30% po), neb (67% inhaled, 30% po)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Convenience sample during office hours, 'open' parallel protocol of iv vs. neb, crossover study for repeaters<BR/>Standard care: O2 at MD discretion, steroids at 120 min with MD discretion, both groups given iv theophylline 6 mg/kg iv at 60 min over 30 min (excluded those pts who already took theophylline)<BR/>Treatment group: salbutamol 0.15 mg/kg NEB at 0 min lasting 7 min, repeat x1 at 30 min (total neb = 0.30 mg/kg in 1 hour) vs. salbutamol 5 ug/kg iv over 10 min at 0 min<BR/>Placebo: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PFTs: PEFR iv 214.7, 210.3, 200, 225, 227.9; neb 235.3, 238.8, 256.2, 276.2, 279.4 <BR/>Timing: 5, 30, 60, 90, 120 min<BR/>Admissions:<BR/>Side effects: iv tremor at 1 hr (35.8 % mild, 9.3% mod, 0% severe), palp at 120 min ( 9%); neb tremor at 1 hr ( 59.8 % mild, 20% mod, 4.2% severe ), palp at 120 min ( 23% )<BR/>Complications:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Co-administration of theophylline at 60 min, no other standard Rx started until 120 min<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-01 09:46:39 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Tribe-1976">
<CHAR_METHODS>
<P>Randomization: yes (method not mentioned)<BR/>Blinding: double-blind<BR/>Number excluded: no details<BR/>Withdrawals: 2<BR/>Baseline characteristics: HR 103.7 iv, 114.6 amino; PaO2 8 kpa iv, 7.6 kpa amino; PaCO2 4.2 kpa iv, 4.5 kpa amino; FEV iv 0.7 (0.3 to 1.7) female, 1.7 (0.3 to 3.1) male, amino 0.7 (0.3 to 1.3) female, 0.7 male<BR/>Jadad score: "strong", score &gt;/= 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Perth, Australia<BR/>Participants: 25 eligible, 23 final (2 lost to follow-up no details given, 11 iv, 12 amino); mean 42 yrs female/ 49 yrs male iv, 48 yrs female/ 17 yrs male amino; males 2 iv, 1 amino; females 9 iv, 11 amino<BR/>Asthma definition and severity: no specified definition, included if demonstrable wheeze or SOB<BR/>Exclusion criteria: arrhythmia, PaO2 &lt; 50, PaCO2 &gt; 50, Pts 'poor general condition', 'too ill to await Rx', allergy, excessive drug Rx in previous 3 hrs<BR/>Inhaled corticosteroid use: 3 iv, 1 theophylline<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Standard care: hydrocortisone 100 mg iv, iv (4 had beta-agonists within 3 hrs prior), neb (5 had beta-agonists within 3 hrs prior) <BR/>Treatment group: theophylline 250 mg iv at 0 min over ?5 min vs. salbutamol 100 ug iv at 0 min<BR/>Placebo: unknown<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PFTs: FEV iv pos 26%; amino pos 23%<BR/>Timing: 60 min<BR/>Admissions:<BR/>Side effects: iv "impression" - 2 (1 HA, 1 tremor &amp; palp), amino "impression" - 3 ( 2 iv pain, 1 HA &amp; vomit )<BR/>Complications:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-01 09:46:39 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Author correspondence:<BR/>Severe co-interventions with beta agonists prior to start of trial, questionable if iv agonists started at truly 0 min<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Van-Renterghem-1987">
<CHAR_METHODS>
<P>Randomization: yes (method not mentioned)<BR/>Blinding: double-blind<BR/>Number excluded: no details<BR/>Withdrawals: none<BR/>Baseline characteristics: HR 114 (sd 21) iv, 113 (sd 17) neb; MAPs 104 (sd 19) iv, 105 (sd 12) neb; PaO2 56.6 (sd 20.7) iv, 63.9 (sd 12.2) neb; PEFR 89.5 (sd 32.4) iv, 97.3 (sd 34.4) neb (predicted PEFR 19.3 % (sd 7) iv, 16.9% (sd 4.5) neb)<BR/>Jadad score: "weak", score &lt; 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Ghent, Belgium<BR/>Participants: 23 (11 iv, 12 neb); mean 49.8 yrs (sd 13.5) iv, 52 yrs (sd 7.6) neb; males 10, females 13<BR/>Asthma definition and severity: all pts "previously demonstrated" an increase of 20% in FEV1 after MDI use, two of three criteria: [1] HR &gt; 100, [2] predPEFR &lt; 30%, [3] PaO2 &lt; 9.3 kpa on 2 lpm O2<BR/>Exclusion criteria: CV Dz, hypoK, hyperGLC, &lt; 2hr iv agonist Rx<BR/>Inhaled corticosteroid use: no details<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Standard care: O2 NPV 30%, hydrocortisone 125 mg iv, theophylline (unknown dose) iv prior to randomization<BR/>Treatment group: terbutaline 0.1 mg/kg NEB over 5 min at 0 min and 60 min vs. terbutaline 6 ug/kg iv over 5 min (q60min x1) at 0 min and 60 min<BR/>Placebo: saline<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PFTs: PEFR/% PEFR Response iv 108 / ?, 104 / ?, 111 / ?, 127.7 (sd 65.4) / 28.2 (sd 12.1); neb 111 / ?, 104 (sd 41.8) / 20.1 (sd 6.7), 111 / ?, 122 (sd 50.1) / ? <BR/>Timing: 15, 30, 60, 120 min<BR/>Admissions:<BR/>Side effects: no details<BR/>Complications:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Run in period with theophylline for unknown time, looks like a few minutes<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Williams-1975">
<CHAR_METHODS>
<P>Randomization: yes (method not mentioned)<BR/>Blinding: double-blind<BR/>Number excluded: no details<BR/>Withdrawals: none<BR/>Baseline characteristics: HR 128 (sd 11) iv, 125 (sd 7) theoph; BP 139 (sd 17) / 87 (sd 9) iv, 157 (sd 20) / 91 (sd 9) theoph; PaO2 7.5 kpa (sd 1.1) iv, 7.7 (sd 1.6) theoph; PaCO2 5.6 kpa (sd 1.2) iv, 5.3 (sd 1.6) theoph; PEFR 75 (sd 15) iv, 90 (sd 20) theoph<BR/>Jadad score: "strong", score &gt;/= 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Penarth, South Glamorgan <BR/>Participants: 20 final (11 salbutamol, 9 theoph)Asthma definition and severity: definition not specified, included if HR &gt; 120, pred PEFR &lt; 25%, PaO2 &lt; 69.8<BR/>Exclusion criteria: none mentioned<BR/>Inhaled corticosteroid use: no details<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Parallel study, iv salbutamol vs. theophylline<BR/>Standard care: O2 NPV 28%, hydrocortisone 1000 mg iv<BR/>Treatment group: aminophylline 500 ug iv at 0 min infused over 60 min vs. salbutamol 500 ug iv at 0 min infused over 60 min (8.33 ug/min)<BR/>Placebo: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PFTs: PEFR iv 114 (sd 27), 128 (sd 53), 161 (sd 85); theoph 109 (sd 34), 118 (sd 43), 134 (sd 64)<BR/>Timing: 15, 30, 60 min<BR/>Admissions:<BR/>Side effects: iv 5 (3 HA, 2 tremor); theoph 7 (2 HA, 3 tremor, 4 nausea, 1 vomit, 4 extrasystoles)<BR/>Complications:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Williams-1981">
<CHAR_METHODS>
<P>Randomization: not applicable<BR/>Blinding: double-blind<BR/>Number excluded: no details<BR/>Withdrawals: none<BR/>Baseline characteristics: HR 124 iv, 117 neb; FEV 0.92 iv first, 1.10 neb first<BR/>Jadad score: "weak", score &lt; 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: London, England <BR/>Participants: 15 final (8 iv/neb, 7 neb/iv)<BR/>Asthma definition and severity: severe acute asthma (otherwise unspecified), PaO2 &lt; 70, HR &gt; 100, pred FEV1 &lt; 25%, run in period of pts able to get consistent FEV1s (within 10% on 3 trials)<BR/>Exclusion criteria: previous 2hr use of any bronchodilators<BR/>Inhaled corticosteroid use: no details<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Crossover of terbutaline iv vs. neb, each repeated twice once FEV was maxed<BR/>Standard care: O2 NPV, hydrocortisone 200 mg iv q6h<BR/>Treatment group: terbutaline 2.5 mg NEB over 10 min (repeat X 2 for each time FEV1 maxed) vs. terbutaline 250 ug iv over 10 min at 0 min (repeat X 2 for each time FEV1 maxed)<BR/>Placebo: saline<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PFTs: FEV pos 0.59 when iv first, pos 0.36 when iv second (these are delta FEV); pos 0.58 when neb first, pos 0.32 when neb second<BR/>Timing: not specified<BR/>Admissions:<BR/>Side effects: 3 tremor unspecified Rx sequence<BR/>Complications:</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author correspondence:<BR/>FEV1 were done on 5 min intervals until no more improvement, but times not listed on graph</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-08-01 09:47:55 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Anonymous-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-experimental study (not randomized controlled clinical trial).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:18 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Arnaud-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:19 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Beswick-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial..</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blumenthal-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter, not a clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:21 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Boe-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:21 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial. Intravenous beta-agonists use was not the primary research question (no control; compared 2 doses of terbutaline - dose response curve).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:22 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Bohn-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:22 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:23 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Bruguerolle-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:23 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crompton-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:25 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Downes-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:25 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:28 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Edmunds-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:28 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:30 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Evans-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:30 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial - cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:31 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Fitchett-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:31 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial - cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grant-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to editor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:33 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Greif-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:33 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial - cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:35 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Herman-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:35 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial - cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:36 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Hetzel-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:36 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial - cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hirsch-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:38 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Iodice-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:38 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial - cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:39 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Janson-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:39 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Marlin-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Chronic asthma.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:40 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-May-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:40 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial - cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nogrady-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Noseda-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:42 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-O_x0027_Connell-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:42 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial - cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:43 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Parry-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:43 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial - cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pierce-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were not seen in an emergency setting (study done in a lab setting).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salmeron-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Letter to editor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:45 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Schiavi-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:45 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-experimental study (not randomized controlled clinical trial).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spiro-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-experimental study (not randomized controlled clinical trial). Patients were not seen in an emergency setting (study done in a lab setting).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:47 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Subias-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:47 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:48 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Teoh-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:48 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Non emergency patients. Not randomized controlled clinical trial - cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thiringer-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-experimental study (not randomized controlled clinical trial). Patients were not seen in an emergency setting (study done in a lab setting).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:50 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Ting-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:50 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:51 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Tirot-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:51 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:52 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Tripathi-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:52 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Williams-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-experimental study (not randomized controlled clinical trial).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:54 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Wood-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:54 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-01 09:47:55 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Wood-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-01 09:47:55 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Not randomized controlled clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-01 09:47:10 +0100" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-08-01 09:47:10 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:44:22 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Bloomfield-1979">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:44:59 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Browne-1997">
<DESCRIPTION>
<P>Investigators unaware as to order of randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:45:10 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Cheong-1988">
<DESCRIPTION>
<P>Sealed envelopes </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:45:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Femi_x002d_Pearse-1-1977">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:45:24 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Femi_x002d_Pearse-2-1977">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:45:27 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hambleton-1979">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:45:30 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Hussein-1986">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:45:34 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1978">
<DESCRIPTION>
<P>Information not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:46:06 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Lawford-1978">
<DESCRIPTION>
<P>Investigators unaware as to order of randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:46:09 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Salmeron-1994">
<DESCRIPTION>
<P>Investigators unaware as to order of randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:46:18 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-1-1984">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:46:25 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Sharma-2-1984">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:46:36 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Swedish-Society-1990">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:46:47 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Tribe-1976">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:46:54 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Van-Renterghem-1987">
<DESCRIPTION>
<P>Information not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:46:58 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Williams-1975">
<DESCRIPTION>
<P>Investigators unaware as to order of randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-01 09:47:10 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="YES" STUDY_ID="STD-Williams-1981">
<DESCRIPTION>
<P>Investigators unaware as to order of randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-08-01 09:51:21 +0100" MODIFIED_BY="Toby J Lasserson">
<COMPARISON ID="CMP-001" MODIFIED="2008-08-01 09:50:29 +0100" MODIFIED_BY="Toby J Lasserson" NO="1">
<NAME>IV vs. All Treatments</NAME>
<CONT_OUTCOME CHI2="4.261250997392002" CI_END="24.605519320419454" CI_START="-4.4347352148508925" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="10.08539205278428" ESTIMABLE="YES" I2="29.59813909492591" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.23460076172356303" P_Q="0.867243333568803" P_Z="0.17340245777432087" Q="0.02794282708539949" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="66.26021016601614" TOTALS="YES" TOTAL_1="130" TOTAL_2="125" UNITS="" WEIGHT="100.0" Z="1.3613520618020751">
<NAME>PEFR ( l/min) @ 15 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.6391819057442896" CI_END="39.65634141734945" CI_START="-27.16975312092805" DF="1" EFFECT_SIZE="6.2432941482107" ESTIMABLE="YES" I2="72.52129665676937" ID="CMP-001.01.01" NO="1" P_CHI2="0.056434852837790817" P_Z="0.7141985642206219" STUDIES="2" TAU2="434.0979775280906" TOTAL_1="99" TOTAL_2="97" WEIGHT="59.079674376725094" Z="0.36622315758325796">
<NAME>Intravenous beta-agonist vs. Inhaled beta-agonist</NAME>
<CONT_DATA CI_END="17.985267126088843" CI_START="-45.98526712608884" EFFECT_SIZE="-14.0" ESTIMABLE="YES" MEAN_1="-137.0" MEAN_2="-123.0" ORDER="1" SD_1="40.8" SD_2="31.6" SE="16.31931371106028" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="16.502443723888288"/>
<CONT_DATA CI_END="36.112721199499404" CI_START="5.087278800500645" EFFECT_SIZE="20.600000000000023" ESTIMABLE="YES" MEAN_1="-214.7" MEAN_2="-235.3" ORDER="2" SD_1="52.8" SD_2="52.2" SE="7.9147991095049415" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="42.57723065283681"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.48613293274808056" CI_END="28.81499727342687" CI_START="-9.74805819519766" DF="1" EFFECT_SIZE="9.533469539114604" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="0.4856574485186037" P_Z="0.3325075118998735" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="28" WEIGHT="40.92032562327491" Z="0.9690755422415579">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="34.33474169456337" CI_START="-36.33474169456337" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-146.0" MEAN_2="-145.0" ORDER="3" SD_1="44.7" SD_2="65.4" SE="18.02826070952288" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="14.026806184094928"/>
<CONT_DATA CI_END="37.009190993980674" CI_START="-9.009190993980674" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="-90.0" MEAN_2="-104.0" ORDER="4" SD_1="25.0" SD_2="27.0" SE="11.739598878078493" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="26.893519439179986"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.36280208559602956" CI_END="17.744626672583717" CI_START="-21.521818591363758" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.8885959593900212" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.8341008238721883" P_Q="0.6692098967596973" P_Z="0.8504560665091896" Q="0.18252772768958955" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="31" UNITS="" WEIGHT="100.0" Z="0.18853655006815306">
<NAME>PEFR ( l/min) @ 30 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.18027435790644009" CI_END="22.56769828577667" CI_START="-21.82893309301859" DF="1" EFFECT_SIZE="0.3693825963790416" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.6711375734093672" P_Z="0.9739823796057191" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="22" WEIGHT="78.22456125249403" Z="0.03261403232338942">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="31.814506246469175" CI_START="-23.814506246469175" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="-128.0" MEAN_2="-132.0" ORDER="5" SD_1="28.7" SD_2="34.5" SE="14.191335384663418" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="49.82421590510218"/>
<CONT_DATA CI_END="30.84086179106091" CI_START="-42.84086179106091" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-110.0" MEAN_2="-104.0" ORDER="6" SD_1="47.8" SD_2="41.8" SE="18.796703450500583" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="11" TOTAL_2="12" WEIGHT="28.40034534739185"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="32.07345085285177" CI_START="-52.07345085285177" DF="0" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.6413275911112847" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="21.775438747505977" Z="0.4658434107044981">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="32.07345085285178" CI_START="-52.07345085285178" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="-128.0" MEAN_2="-118.0" ORDER="7" SD_1="53.0" SD_2="43.0" SE="21.466440804383033" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="21.775438747505977"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5488174442640107" CI_END="29.094147127178317" CI_START="-29.941185351966155" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.42351911239391893" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2008-08-01 09:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.7600213925063175" P_Q="0.46375338406458" P_Z="0.9775652150985257" Q="0.5368207584072022" RANDOM="YES" SCALE="147.22451359683205" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="0.028121539159610805">
<NAME>PEFR ( l/min) @ 45 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.011996685856808501" CI_END="39.67984060713755" CI_START="-28.087676676632057" DF="1" EFFECT_SIZE="5.796081965252745" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="0.9127826187046978" P_Z="0.7374235563689759" STUDIES="2" TAU2="0.0" TOTAL_1="16" TOTAL_2="17" WEIGHT="75.88935759304668" Z="0.3352671710184749">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="41.75651054219" CI_START="-31.75651054219" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="-124.0" MEAN_2="-129.0" ORDER="8" SD_1="43.6" SD_2="40.2" SE="18.753666308218243" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="64.49046156768046"/>
<CONT_DATA CI_END="97.72801571716448" CI_START="-77.12801571716449" EFFECT_SIZE="10.299999999999997" ESTIMABLE="YES" MEAN_1="-123.3" MEAN_2="-133.6" ORDER="9" SD_1="87.0" SD_2="71.4" SE="44.606950131117465" STUDY_ID="STD-Lawford-1978" TOTAL_1="6" TOTAL_2="7" WEIGHT="11.39889602536623"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="40.114276815673" CI_START="-80.11427681567301" DF="0" EFFECT_SIZE="-20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="1.0" P_Z="0.5143499764996509" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="24.11064240695331" Z="0.6520793689491918">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="40.114276815673" CI_START="-80.11427681567301" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="-151.0" MEAN_2="-131.0" ORDER="10" SD_1="72.0" SD_2="65.0" SE="30.671112984650097" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="24.11064240695331"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="18.83211824757556" CI_END="42.53259150569535" CI_START="-3.693182313532187" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="19.41970459608158" ESTIMABLE="YES" I2="68.13953735250979" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2008-08-01 09:49:36 +0100" MODIFIED_BY="Toby J Lasserson" NO="4" P_CHI2="0.004456763211511339" P_Q="0.39095043006790575" P_Z="0.09960254690578148" Q="0.7359839674075237" RANDOM="YES" SCALE="132.284910007066" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="596.4260054646314" TOTALS="YES" TOTAL_1="203" TOTAL_2="193" UNITS="" WEIGHT="100.0" Z="1.6467835345525386">
<NAME>PEFR ( l/min) @ 60 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="15.530227100344092" CI_END="52.34321556094834" CI_START="-2.922027660745808" DF="4" EFFECT_SIZE="24.710593950101266" ESTIMABLE="YES" I2="74.243776513021" ID="CMP-001.04.01" NO="1" P_CHI2="0.003718890887327686" P_Z="0.07965240768359903" STUDIES="5" TAU2="681.9108218821779" TOTAL_1="172" TOTAL_2="165" WEIGHT="76.91582358691419" Z="1.7527064518474824">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="29.073522651339943" CI_START="-53.07352265133994" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="-137.0" MEAN_2="-125.0" ORDER="11" SD_1="45.9" SD_2="47.8" SE="20.95626398001323" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="13.428389718268706"/>
<CONT_DATA CI_END="32.683688388048324" CI_START="-10.483688388048332" EFFECT_SIZE="11.099999999999994" ESTIMABLE="YES" MEAN_1="-137.9" MEAN_2="-149.0" ORDER="12" SD_1="37.2" SD_2="53.4" SE="11.012288265650648" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" WEIGHT="19.376323617087014"/>
<CONT_DATA CI_END="100.47276076274335" CI_START="1.5272392372566443" EFFECT_SIZE="51.0" ESTIMABLE="YES" MEAN_1="-123.0" MEAN_2="-174.0" ORDER="13" SD_1="82.0" SD_2="90.0" SE="25.241668292365663" STUDY_ID="STD-Salmeron-1994" TOTAL_1="25" TOTAL_2="22" WEIGHT="11.273250925924337"/>
<CONT_DATA CI_END="75.28063808369018" CI_START="37.1193619163098" EFFECT_SIZE="56.19999999999999" ESTIMABLE="YES" MEAN_1="-200.0" MEAN_2="-256.2" ORDER="14" SD_1="58.5" SD_2="70.0" SE="9.735198317007775" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="20.119093987942044"/>
<CONT_DATA CI_END="55.69199976487419" CI_START="-31.69199976487419" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="-99.0" MEAN_2="-111.0" ORDER="15" SD_1="40.8" SD_2="64.4" SE="22.292246239987627" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="12.71876533769208"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.320610920582593" CI_END="42.86149921792305" CI_START="-35.36303231962538" DF="1" EFFECT_SIZE="3.749233449148835" ESTIMABLE="YES" I2="24.27747003948402" ID="CMP-001.04.02" NO="2" P_CHI2="0.2504825756004674" P_Z="0.8509717227208524" STUDIES="2" TAU2="231.81220879851102" TOTAL_1="31" TOTAL_2="28" WEIGHT="23.08417641308582" Z="0.18787872258301286">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="52.52695628312136" CI_START="-19.12695628312138" EFFECT_SIZE="16.69999999999999" ESTIMABLE="YES" MEAN_1="-133.3" MEAN_2="-150.0" ORDER="16" SD_1="46.1" SD_2="65.8" SE="18.279395216299804" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="14.943996426412937"/>
<CONT_DATA CI_END="38.35618249493628" CI_START="-92.35618249493628" EFFECT_SIZE="-27.0" ESTIMABLE="YES" MEAN_1="-161.0" MEAN_2="-134.0" ORDER="17" SD_1="85.0" SD_2="64.0" SE="33.34560380213999" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="8.140179986672885"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0704077500707276" CI_END="68.42169643225738" CI_START="25.931471865170494" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="47.176584148713935" ESTIMABLE="YES" I2="6.577656978480903" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.30085377244264633" P_Q="1.0" P_Z="1.3473689540273839E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="32.63340068448831" TOTALS="YES" TOTAL_1="99" TOTAL_2="97" UNITS="" WEIGHT="100.00000000000001" Z="4.352267223210953">
<NAME>PEFR ( l/min) @ 120 min</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0704077500707276" CI_END="68.42169643225738" CI_START="25.931471865170494" DF="1" EFFECT_SIZE="47.176584148713935" ESTIMABLE="YES" I2="6.577656978480903" ID="CMP-001.05.01" NO="1" P_CHI2="0.30085377244264633" P_Z="1.3473689540273839E-5" STUDIES="2" TAU2="32.63340068448831" TOTAL_1="99" TOTAL_2="97" WEIGHT="100.00000000000001" Z="4.352267223210953">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="76.24205361884773" CI_START="-36.242053618847734" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="-157.0" MEAN_2="-177.0" ORDER="18" SD_1="57.5" SD_2="70.2" SE="28.695452601414043" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="13.725129686622338"/>
<CONT_DATA CI_END="71.444903854144" CI_START="31.55509614585594" EFFECT_SIZE="51.49999999999997" ESTIMABLE="YES" MEAN_1="-227.9" MEAN_2="-279.4" ORDER="19" SD_1="67.9" SD_2="67.1" SE="10.176158343452679" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="86.27487031337768"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.02096559443850975" CI_END="47.6313100129165" CI_START="-9.356315718336251" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="19.137497147290127" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.9895719563098114" P_Q="0.9421264579437386" P_Z="0.18804512151812708" Q="0.005270389401596088" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="51" UNITS="" WEIGHT="100.0" Z="1.3163842038204572">
<NAME>PEFR ( l/min) Final</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.015695205036913656" CI_END="62.874909554727864" CI_START="-27.182871884174787" DF="1" EFFECT_SIZE="17.84601883527654" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="0.900301488665308" P_Z="0.4372884218890015" STUDIES="2" TAU2="0.0" TOTAL_1="22" TOTAL_2="32" WEIGHT="40.04226531018001" Z="0.7767802765226915">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="76.24205361884773" CI_START="-36.242053618847734" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="-157.0" MEAN_2="-177.0" ORDER="20" SD_1="57.5" SD_2="70.2" SE="28.695452601414043" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="25.667217765015437"/>
<CONT_DATA CI_END="89.1529309810806" CI_START="-61.1529309810806" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="-240.0" MEAN_2="-254.0" ORDER="21" SD_1="115.0" SD_2="90.0" SE="38.34403671387705" STUDY_ID="STD-Salmeron-1994" TOTAL_1="12" TOTAL_2="22" WEIGHT="14.375047545164572"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="56.79831728522501" CI_START="-16.79831728522501" DF="0" EFFECT_SIZE="20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="1.0" P_Z="0.2867643996892323" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="59.95773468982" Z="1.065246527088892">
<NAME>Intravenous beta-agonist vs.intravenous methylxanthine</NAME>
<CONT_DATA CI_END="56.79831728522501" CI_START="-16.79831728522501" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="-148.0" MEAN_2="-168.0" ORDER="22" SD_1="46.1" SD_2="68.4" SE="18.774996671104898" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="59.95773468982"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1053465662034778" CI_END="2.333117087554909" CI_START="-8.684598351930337" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.1757406321877135" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.9536293674403632" P_Q="0.3541953930132822" P_Z="0.25852764468549017" Q="0.8583697525312968" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="1.1298780219030937">
<NAME>Arterial Oxygen Tension (mm Hg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.24697681367218077" CI_END="6.718431722543" CI_START="-8.267862158500765" DF="3" EFFECT_SIZE="-0.7747152179788827" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="0.9696713730168341" P_Z="0.8394161489000306" STUDIES="4" TAU2="0.0" TOTAL_1="36" TOTAL_2="37" WEIGHT="54.0498649476455" Z="0.20264035091882945">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="17.68665038763601" CI_START="-15.68665038763601" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-92.0" MEAN_2="-93.0" ORDER="23" SD_1="24.0" SD_2="12.2" SE="8.513753578768885" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="10.898952950384686"/>
<CONT_DATA CI_END="10.394278682622586" CI_START="-10.394278682622586" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-72.5" MEAN_2="-72.5" ORDER="24" SD_1="11.25" SD_2="11.25" SE="5.303300858899107" STUDY_ID="STD-Hussein-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="28.088878423313194"/>
<CONT_DATA CI_END="26.049174075880465" CI_START="-39.049174075880465" EFFECT_SIZE="-6.5" ESTIMABLE="YES" MEAN_1="-90.4" MEAN_2="-83.9" ORDER="25" SD_1="16.0" SD_2="37.4" SE="16.607026625297298" STUDY_ID="STD-Lawford-1978" TOTAL_1="6" TOTAL_2="6" WEIGHT="2.8644626616150384"/>
<CONT_DATA CI_END="12.97338413378858" CI_START="-18.573384133788586" EFFECT_SIZE="-2.8000000000000043" ESTIMABLE="YES" MEAN_1="-66.7" MEAN_2="-63.9" ORDER="26" SD_1="24.0" SD_2="12.2" SE="8.04779284630076" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="12.197570912332585"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.588389701024356E-32" CI_END="2.126773573134586" CI_START="-14.126773573134585" DF="1" EFFECT_SIZE="-5.999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="0.9999999999999998" P_Z="0.1478851186262167" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="28" WEIGHT="45.9501350523545" Z="1.4470421504194129">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="5.208017040785592" CI_START="-17.20801704078559" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-62.25" MEAN_2="-56.25" ORDER="27" SD_1="10.1" SD_2="22.9" SE="5.718481119649646" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="24.15825417914292"/>
<CONT_DATA CI_END="5.800874661355918" CI_START="-17.80087466135592" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="-66.7" MEAN_2="-60.7" ORDER="28" SD_1="14.2" SD_2="12.7" SE="6.020965055704957" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="21.791880873211575"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.691896886648305" CI_END="4.253243942431584" CI_START="-0.940830026198558" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="1.6562069581165129" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2008-08-01 09:49:57 +0100" MODIFIED_BY="Toby J Lasserson" NO="8" P_CHI2="0.44930565723767446" P_Q="0.5170972280524757" P_Z="0.21132633212521423" Q="0.4196790998655922" RANDOM="YES" SCALE="24.5773518923273" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="1.2499267466955672">
<NAME>Arterial Carbon Dioxide Tension (mm Hg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.132108182862903" CI_END="9.049556505778751" CI_START="-2.685272394177005" DF="2" EFFECT_SIZE="3.182142055800873" ESTIMABLE="YES" I2="36.14524520759369" ID="CMP-001.08.01" NO="1" P_CHI2="0.2088678391554598" P_Z="0.2877957046915346" STUDIES="3" TAU2="9.777988777310094" TOTAL_1="40" TOTAL_2="37" WEIGHT="31.650550806273642" Z="1.0629697077361688">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="6.92951912174839" CI_START="-6.92951912174839" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="30.0" ORDER="29" SD_1="7.5" SD_2="7.5" SE="3.5355339059327378" STUDY_ID="STD-Hussein-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="14.045916226547734"/>
<CONT_DATA CI_END="10.277909163809458" CI_START="-9.277909163809458" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="36.9" MEAN_2="36.4" ORDER="30" SD_1="9.8" SD_2="7.3" SE="4.988820835962476" STUDY_ID="STD-Lawford-1978" TOTAL_1="6" TOTAL_2="6" WEIGHT="7.05446807065613"/>
<CONT_DATA CI_END="16.99555246664878" CI_START="1.0044475333512226" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="49.0" MEAN_2="40.0" ORDER="31" SD_1="18.0" SD_2="9.0" SE="4.079438464031316" STUDY_ID="STD-Salmeron-1994" TOTAL_1="25" TOTAL_2="22" WEIGHT="10.550166509069777"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0012539748264553943" CI_END="4.1236423960408155" CI_START="-2.1589751167364484" DF="1" EFFECT_SIZE="0.9823336396521837" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" NO="2" P_CHI2="0.9717516121865396" P_Z="0.5399360636249788" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="28" WEIGHT="68.34944919372636" Z="0.6129096831391607">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="4.289972153899678" CI_START="-2.289972153899677" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="38.25" MEAN_2="37.25" ORDER="32" SD_1="6.7" SD_2="3.3" SE="1.6785880658270038" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="62.312019198570795"/>
<CONT_DATA CI_END="11.369442499066668" CI_START="-9.769442499066674" EFFECT_SIZE="0.7999999999999972" ESTIMABLE="YES" MEAN_1="39.0" MEAN_2="38.2" ORDER="33" SD_1="6.7" SD_2="15.0" SE="5.3926717952151595" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="6.037429995155564"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.692271487899946" CI_END="14.512266715575429" CI_START="0.8669764231999952" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="7.689621569387712" ESTIMABLE="YES" I2="53.98210921543132" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2008-08-01 09:50:03 +0100" MODIFIED_BY="Toby J Lasserson" NO="9" P_CHI2="0.06926876637928425" P_Q="0.9750858809611669" P_Z="0.027173028102763567" Q="9.753313567129285E-4" RANDOM="YES" SCALE="49.75079649579115" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="30.624685415797046" TOTALS="YES" TOTAL_1="141" TOTAL_2="137" UNITS="" WEIGHT="100.0" Z="2.2090231879000344">
<NAME>Heart Rate @ 15 min</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.120629448204195" CI_END="20.10228689776104" CI_START="-3.392474067014133" DF="2" EFFECT_SIZE="8.354906415373454" ESTIMABLE="YES" I2="71.91259544471318" ID="CMP-001.09.01" NO="1" P_CHI2="0.028429921789920654" P_Z="0.16333129916788594" STUDIES="3" TAU2="76.09070242114483" TOTAL_1="110" TOTAL_2="109" WEIGHT="63.38074691287401" Z="1.3939546516677077">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="34.351081311933086" CI_START="7.648918688066917" EFFECT_SIZE="21.0" ESTIMABLE="YES" MEAN_1="148.0" MEAN_2="127.0" ORDER="34" SD_1="13.1" SD_2="17.1" SE="6.811901349843522" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="15.731429034728727"/>
<CONT_DATA CI_END="6.151559878819769" CI_START="-2.1515598788197687" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="107.0" MEAN_2="105.0" ORDER="35" SD_1="14.1" SD_2="14.0" SE="2.1181817174023316" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="34.51131407763389"/>
<CONT_DATA CI_END="20.38377837719525" CI_START="-10.383778377195247" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="118.0" MEAN_2="113.0" ORDER="36" SD_1="22.2" SD_2="14.2" SE="7.849010746391529" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="13.138003800511392"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6848243277443262" CI_END="16.368312409351724" CI_START="-0.11581995555016711" DF="1" EFFECT_SIZE="8.12624622690078" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.02" NO="2" P_CHI2="0.40793079267650356" P_Z="0.0533074420388335" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="28" WEIGHT="36.619253087126" Z="1.9324219900274775">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="16.079473202028836" CI_START="-6.079473202028838" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="115.0" MEAN_2="110.0" ORDER="37" SD_1="17.9" SD_2="17.4" SE="5.6528963233111975" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="19.363076713409825"/>
<CONT_DATA CI_END="24.333136188891583" CI_START="-0.3331361888915829" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="128.0" MEAN_2="116.0" ORDER="38" SD_1="14.0" SD_2="14.0" SE="6.292532049656926" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="17.256176373716173"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="11.814889100559455" CI_END="11.032461538149628" CI_START="-2.9757224500189405" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="4.0283695440653435" ESTIMABLE="YES" I2="66.1444134942359" I2_Q="20.916872869870915" ID="CMP-001.10" MODIFIED="2008-08-01 09:50:09 +0100" MODIFIED_BY="Toby J Lasserson" NO="10" P_CHI2="0.018782234927484986" P_Q="0.26080257879756263" P_Z="0.25963098949580377" Q="1.2644922327799808" RANDOM="YES" SCALE="46.086947862041846" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="38.041555884609565" TOTALS="YES" TOTAL_1="158" TOTAL_2="152" UNITS="" WEIGHT="100.0" Z="1.1272637808661972">
<NAME>Heart Rate @ 30 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.617491501545361" CI_END="9.790586175274564" CI_START="-4.690230668960407" DF="3" EFFECT_SIZE="2.550177753157078" ESTIMABLE="YES" I2="65.18708490212012" ID="CMP-001.10.01" NO="1" P_CHI2="0.034833595262012906" P_Z="0.4899879582382466" STUDIES="4" TAU2="32.56844104379792" TOTAL_1="147" TOTAL_2="143" WEIGHT="84.2066167980003" Z="0.690327984136203">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="24.112012903282967" CI_START="-4.112012903282965" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="136.0" MEAN_2="126.0" ORDER="39" SD_1="16.1" SD_2="16.1" SE="7.200138887549323" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="14.20781377177393"/>
<CONT_DATA CI_END="11.28023003787943" CI_START="-3.2802300378794307" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="105.0" MEAN_2="101.0" ORDER="40" SD_1="14.0" SD_2="17.0" SE="3.7144713348331684" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" WEIGHT="24.634974440350685"/>
<CONT_DATA CI_END="-0.3586100020886942" CI_START="-8.441389997911317" EFFECT_SIZE="-4.400000000000006" ESTIMABLE="YES" MEAN_1="98.0" MEAN_2="102.4" ORDER="41" SD_1="12.3" SD_2="14.9" SE="2.0619715616150502" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="30.195074595291107"/>
<CONT_DATA CI_END="21.314472427626274" CI_START="-5.314472427626274" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="119.0" MEAN_2="111.0" ORDER="42" SD_1="17.2" SD_2="15.2" SE="6.79322300442719" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="15.168753990584579"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.369401237733444E-32" CI_END="23.82514258133372" CI_START="-1.825142581333722" DF="0" EFFECT_SIZE="10.999999999999998" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.10.02" NO="2" P_CHI2="0.0" P_Z="0.09275474936821891" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="15.793383201999701" Z="1.6810420385750249">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="23.825142581333722" CI_START="-1.8251425813337203" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="126.0" MEAN_2="115.0" ORDER="43" SD_1="14.0" SD_2="15.0" SE="6.543560331973857" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="15.793383201999701"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.594362620458498" CI_END="24.458734019142824" CI_START="1.5750244600754915" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="13.016879239609159" ESTIMABLE="YES" I2="44.35731140157252" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2008-08-01 09:50:15 +0100" MODIFIED_BY="Toby J Lasserson" NO="11" P_CHI2="0.16576553400117366" P_Q="0.38743481694821535" P_Z="0.025763238646902352" Q="0.7469777436841659" RANDOM="YES" SCALE="85.95654740198617" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="45.72287334015222" TOTALS="YES" TOTAL_1="28" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="2.2297621314313596">
<NAME>Heart Rate @ 45 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.654169064419702" CI_END="39.18949107059669" CI_START="-2.569861687060328" DF="1" EFFECT_SIZE="18.309814691768178" ESTIMABLE="YES" I2="62.323424931537424" ID="CMP-001.11.01" NO="1" P_CHI2="0.10327876937620728" P_Z="0.08566310025983889" STUDIES="2" TAU2="144.0450158730158" TOTAL_1="17" TOTAL_2="19" WEIGHT="54.27433822670772" Z="1.7187324510381836">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="23.682210432427112" CI_START="-5.682210432427114" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="129.0" MEAN_2="120.0" ORDER="44" SD_1="15.4" SD_2="18.0" SE="7.4910613400238555" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="33.464404006512005"/>
<CONT_DATA CI_END="51.7946247461406" CI_START="9.205375253859398" EFFECT_SIZE="30.5" ESTIMABLE="YES" MEAN_1="135.4" MEAN_2="104.9" ORDER="45" SD_1="17.1" SD_2="26.2" SE="10.864804105641678" STUDY_ID="STD-Lawford-1978" TOTAL_1="7" TOTAL_2="9" WEIGHT="20.809934220195714"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="18.519746010596986" CI_START="-2.519746010596986" DF="0" EFFECT_SIZE="8.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.02" NO="2" P_CHI2="1.0" P_Z="0.13609205601025254" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="45.72566177329227" Z="1.4905028943213643">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="18.519746010596986" CI_START="-2.519746010596986" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="126.0" MEAN_2="118.0" ORDER="46" SD_1="13.0" SD_2="11.0" SE="5.367315978036025" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="45.72566177329227"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="31.229704138607538" CI_END="10.188884518441194" CI_START="-2.898687881765318" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="3.6450983183379377" ESTIMABLE="YES" I2="74.3833628250418" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2008-08-01 09:48:23 +0100" MODIFIED_BY="Toby J Lasserson" NO="12" P_CHI2="1.2787240460077065E-4" P_Q="0.7607940318551237" P_Z="0.27493745272814707" Q="0.0926826616261329" RANDOM="YES" SCALE="34.45379151475034" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="68.52932569599616" TOTALS="YES" TOTAL_1="223" TOTAL_2="214" UNITS="" WEIGHT="100.0" Z="1.0917626593511176">
<NAME>Heart Rate @ 60 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="25.73380554574284" CI_END="13.97907345238973" CI_START="-4.891806012924999" DF="5" EFFECT_SIZE="4.543633719732366" ESTIMABLE="YES" I2="80.57030472577286" ID="CMP-001.12.01" NO="1" P_CHI2="1.0049367089215444E-4" P_Z="0.345261556720205" STUDIES="6" TAU2="102.1351792040009" TOTAL_1="181" TOTAL_2="174" WEIGHT="64.47538315132756" Z="0.9438201824123276">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="24.994746747057242" CI_START="-2.9947467470572438" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="129.0" MEAN_2="118.0" ORDER="47" SD_1="12.2" SD_2="19.0" SE="7.1403081166011315" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="9.327079732921224"/>
<CONT_DATA CI_END="15.44488594622647" CI_START="0.5551140537735293" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="114.0" MEAN_2="106.0" ORDER="48" SD_1="17.0" SD_2="15.0" SE="3.7984809950339806" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" WEIGHT="13.43707931916065"/>
<CONT_DATA CI_END="34.208647004088306" CI_START="-4.208647004088309" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="155.0" MEAN_2="140.0" ORDER="49" SD_1="17.4" SD_2="23.7" SE="9.800510190801292" STUDY_ID="STD-Hussein-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="6.773088376678515"/>
<CONT_DATA CI_END="17.62168316833518" CI_START="-3.621683168335183" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="122.0" MEAN_2="115.0" ORDER="50" SD_1="18.0" SD_2="19.0" SE="5.4193256876747045" STUDY_ID="STD-Salmeron-1994" TOTAL_1="25" TOTAL_2="22" WEIGHT="11.386397825102469"/>
<CONT_DATA CI_END="-4.945932567930403" CI_START="-15.054067432069598" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="105.0" ORDER="51" SD_1="14.1" SD_2="19.6" SE="2.578653216046537" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="14.82745990313704"/>
<CONT_DATA CI_END="18.085579670297577" CI_START="-12.085579670297575" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="117.0" MEAN_2="114.0" ORDER="52" SD_1="19.9" SD_2="16.7" SE="7.696865753294806" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="8.72427799432767"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.7738059848925145" CI_END="11.357799930738171" CI_START="-6.283028593924523" DF="2" EFFECT_SIZE="2.5373856684068246" ESTIMABLE="YES" I2="58.10470709682536" ID="CMP-001.12.02" NO="2" P_CHI2="0.09191414536779541" P_Z="0.5728721233507703" STUDIES="3" TAU2="35.269188474500965" TOTAL_1="42" TOTAL_2="40" WEIGHT="35.524616848672444" Z="0.5638266386425929">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="17.381014612156548" CI_START="-2.581014612156535" EFFECT_SIZE="7.400000000000006" ESTIMABLE="YES" MEAN_1="115.4" MEAN_2="108.0" ORDER="53" SD_1="16.5" SD_2="15.3" SE="5.092447968883873" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="11.800577628789739"/>
<CONT_DATA CI_END="3.223334816036017" CI_START="-14.423334816036006" EFFECT_SIZE="-5.599999999999994" ESTIMABLE="YES" MEAN_1="101.0" MEAN_2="106.6" ORDER="54" SD_1="9.3" SD_2="12.2" SE="4.501784158093389" STUDY_ID="STD-Tribe-1976" TOTAL_1="11" TOTAL_2="12" WEIGHT="12.553696361218703"/>
<CONT_DATA CI_END="17.958744974431582" CI_START="-3.9587449744315837" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="126.0" MEAN_2="119.0" ORDER="55" SD_1="14.0" SD_2="11.0" SE="5.5912991569604165" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="11.170342858663998"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="41.41066019517423" CI_END="14.95460249864367" CI_START="-9.269675401396224" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="2.8424635486237237" ESTIMABLE="YES" I2="90.34065146233496" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2008-08-01 09:50:25 +0100" MODIFIED_BY="Toby J Lasserson" NO="13" P_CHI2="2.2098333385400792E-8" P_Q="1.0" P_Z="0.64554334811099" Q="0.0" RANDOM="YES" SCALE="48.088986119357756" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="166.2683243046818" TOTALS="YES" TOTAL_1="159" TOTAL_2="162" UNITS="" WEIGHT="100.0" Z="0.459962208628827">
<NAME>Heart Rate @ 120 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="41.41066019517423" CI_END="14.95460249864367" CI_START="-9.269675401396224" DF="4" EFFECT_SIZE="2.8424635486237237" ESTIMABLE="YES" I2="90.34065146233496" ID="CMP-001.13.01" NO="1" P_CHI2="2.2098333385400792E-8" P_Z="0.64554334811099" STUDIES="5" TAU2="166.2683243046818" TOTAL_1="159" TOTAL_2="162" WEIGHT="100.0" Z="0.459962208628827">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="8.195230996385067" CI_START="-18.195230996385067" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="118.0" MEAN_2="123.0" ORDER="56" SD_1="18.9" SD_2="9.8" SE="6.73238442158497" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="18.048601037504312"/>
<CONT_DATA CI_END="19.2214810355241" CI_START="4.778518964475898" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="113.0" MEAN_2="101.0" ORDER="57" SD_1="17.0" SD_2="14.0" SE="3.6844968032505814" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" WEIGHT="21.23488617338981"/>
<CONT_DATA CI_END="26.125913712850213" CI_START="3.8740862871497885" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="126.0" MEAN_2="111.0" ORDER="58" SD_1="15.0" SD_2="16.0" SE="5.676590896878717" STUDY_ID="STD-Salmeron-1994" TOTAL_1="12" TOTAL_2="19" WEIGHT="19.23988537947544"/>
<CONT_DATA CI_END="-6.6993264224911275" CI_START="-15.300673577508872" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="105.0" ORDER="59" SD_1="15.1" SD_2="14.0" SE="2.1942615330853203" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="22.322270957429144"/>
<CONT_DATA CI_END="15.277885508958784" CI_START="-7.277885508958784" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="114.0" MEAN_2="110.0" ORDER="60" SD_1="14.3" SD_2="13.2" SE="5.754128952326321" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="19.154356452201302"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.13.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.906365015731062" CI_END="16.639495152446163" CI_START="5.000843202234847" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="10.820169177340505" ESTIMABLE="YES" I2="49.52739988825241" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2008-08-01 09:50:29 +0100" MODIFIED_BY="Toby J Lasserson" NO="14" P_CHI2="0.07793238987447737" P_Q="0.9020887039939676" P_Z="2.6816133426528477E-4" Q="0.015134715753777245" RANDOM="YES" SCALE="53.695090128063335" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="25.04987497901495" TOTALS="YES" TOTAL_1="98" TOTAL_2="94" UNITS="" WEIGHT="100.0" Z="3.6442608619862944">
<NAME>Heart Rate Final</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.65086454177095" CI_END="18.010957142838283" CI_START="3.4436030909658166" DF="4" EFFECT_SIZE="10.72728011690205" ESTIMABLE="YES" I2="58.55293603296194" ID="CMP-001.14.01" NO="1" P_CHI2="0.04673798345277136" P_Z="0.0038942547601646393" STUDIES="5" TAU2="38.52977176727474" TOTAL_1="78" TOTAL_2="75" WEIGHT="80.91379980336025" Z="2.886602825239647">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="8.195230996385067" CI_START="-18.195230996385067" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="118.0" MEAN_2="123.0" ORDER="61" SD_1="18.9" SD_2="9.8" SE="6.73238442158497" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="12.526552191370874"/>
<CONT_DATA CI_END="21.072958148238506" CI_START="-1.0729581482385058" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="152.0" MEAN_2="142.0" ORDER="62" SD_1="18.9" SD_2="9.8" SE="5.649572255194783" STUDY_ID="STD-Browne-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="15.474681176674167"/>
<CONT_DATA CI_END="24.61647405129481" CI_START="11.38352594870519" EFFECT_SIZE="18.0" ESTIMABLE="YES" MEAN_1="116.0" MEAN_2="98.0" ORDER="63" SD_1="14.0" SD_2="14.4" SE="3.375814098363395" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" WEIGHT="24.187967015223624"/>
<CONT_DATA CI_END="30.153956100279338" CI_START="-2.1539561002793377" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="152.0" MEAN_2="138.0" ORDER="64" SD_1="20.1" SD_2="14.4" SE="8.241965784932622" STUDY_ID="STD-Hussein-1986" TOTAL_1="9" TOTAL_2="9" WEIGHT="9.481132821320665"/>
<CONT_DATA CI_END="20.930365558966088" CI_START="3.0696344410339123" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="114.0" MEAN_2="102.0" ORDER="65" SD_1="8.2" SD_2="9.3" SE="4.556392683440957" STUDY_ID="STD-Williams-1981" TOTAL_1="8" TOTAL_2="7" WEIGHT="19.243466598770926"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="19.011185504082334" CI_START="0.9888144959176639" DF="0" EFFECT_SIZE="10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.02" NO="2" P_CHI2="1.0" P_Z="0.029627527087672096" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="19.086200196639748" Z="2.1750345541684077">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="19.011185504082334" CI_START="0.9888144959176639" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="114.0" MEAN_2="104.0" ORDER="66" SD_1="14.3" SD_2="14.4" SE="4.5976281070271785" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="19.086200196639748"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.954401924934409" CI_END="4.373854099817691" CI_START="-10.995011515686638" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.310578707934474" ESTIMABLE="YES" I2="87.46427469102248" I2_Q="86.34110497419218" ID="CMP-001.15" MODIFIED="2008-08-01 09:48:31 +0100" MODIFIED_BY="Toby J Lasserson" NO="15" P_CHI2="3.432006780734742E-4" P_Q="0.006814481752988266" P_Z="0.39845465612186226" Q="7.321236440506708" RANDOM="YES" SCALE="25.449315515463425" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="39.02749175279399" TOTALS="YES" TOTAL_1="120" TOTAL_2="115" UNITS="" WEIGHT="99.99999999999999" Z="0.8443843804569297">
<NAME>Diastolic Blood Pressure @ 60 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.3903950348378493E-31" CI_END="5.334259892717089" CI_START="0.6657401072829119" DF="0" EFFECT_SIZE="3.0000000000000004" ESTIMABLE="YES" I2="100.0" ID="CMP-001.15.01" NO="1" P_CHI2="0.0" P_Z="0.011770422469821759" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="87" WEIGHT="38.006065686740456" Z="2.5189534258655084">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<CONT_DATA CI_END="5.334259892717089" CI_START="0.6657401072829114" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="84.0" MEAN_2="81.0" ORDER="67" SD_1="8.0" SD_2="7.8" SE="1.1909708092237574" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="38.006065686740456"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.230541298737505" CI_END="-0.10661013638889383" CI_START="-13.584311106111297" DF="1" EFFECT_SIZE="-6.845460621250095" ESTIMABLE="YES" I2="55.167833002419464" ID="CMP-001.15.02" NO="2" P_CHI2="0.13530653339371623" P_Z="0.04648406925952003" STUDIES="2" TAU2="13.516119085592763" TOTAL_1="31" TOTAL_2="28" WEIGHT="61.99393431325953" Z="1.9909710573603439">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<CONT_DATA CI_END="0.9591757111610981" CI_START="-8.959175711161098" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="75.0" MEAN_2="79.0" ORDER="68" SD_1="8.0" SD_2="7.8" SE="2.530238183088283" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="33.836744227455156"/>
<CONT_DATA CI_END="-3.2672883983665315" CI_START="-18.73271160163347" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="73.0" MEAN_2="84.0" ORDER="69" SD_1="7.0" SD_2="10.0" SE="3.945333517670789" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="28.157190085804377"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="44.95070595095812" CI_END="0.9472869051842363" CI_START="0.37553508063219965" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5964389862510574" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="93" I2="82.20272667413029" I2_Q="90.17102684888332" ID="CMP-001.16" LOG_CI_END="-0.023518466120899667" LOG_CI_START="-0.42534948711957465" LOG_EFFECT_SIZE="-0.22443397662023717" METHOD="PETO" MODIFIED="2008-08-01 09:48:38 +0100" MODIFIED_BY="Toby J Lasserson" NO="16" P_CHI2="3.7600198499188053E-7" P_Q="0.001424358675454096" P_Z="0.02856846915651257" Q="10.174002763313965" RANDOM="NO" SCALE="165.46780978616547" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="195" TOTAL_2="185" WEIGHT="100.00000000000001" Z="2.189390505439449">
<NAME>Autonomic Side Effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="26.58187640887243" CI_END="0.651717823297308" CI_START="0.22171291065805032" DF="4" EFFECT_SIZE="0.38012400020384807" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="76" I2="84.95215334510813" ID="CMP-001.16.01" LOG_CI_END="-0.1859404016776795" LOG_CI_START="-0.6542090165639366" LOG_EFFECT_SIZE="-0.420074709120808" NO="1" P_CHI2="2.4147996000256633E-5" P_Z="4.3729066951938905E-4" STUDIES="5" TAU2="0.0" TOTAL_1="153" TOTAL_2="144" WEIGHT="73.63712435381206" Z="3.5164914944936516">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<DICH_DATA CI_END="90.9965173947678" CI_START="1.2702055840857227" EFFECT_SIZE="10.751013186076355" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.95902477138508" LOG_CI_START="0.10387401765536639" LOG_EFFECT_SIZE="1.031449394520223" ORDER="70" O_E="2.0" SE="1.0897247358851685" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" VAR="0.8421052631578947" WEIGHT="4.691681344037367"/>
<DICH_DATA CI_END="114.55394450877218" CI_START="0.4284474579307903" EFFECT_SIZE="7.005736672237135" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.059010048120785" LOG_CI_START="-0.36810242958638467" LOG_EFFECT_SIZE="0.8454538092672002" ORDER="71" O_E="0.9577464788732395" SE="1.4256978838057217" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" VAR="0.4919772154051067" WEIGHT="2.740987883809016"/>
<DICH_DATA CI_END="79.67413201437259" CI_START="0.873261065503689" EFFECT_SIZE="8.341241958842375" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.901317340882241" LOG_CI_START="-0.05885590250480874" LOG_EFFECT_SIZE="0.9212307191887161" ORDER="72" O_E="1.6" SE="1.151415466179596" STUDY_ID="STD-Lawford-1978" TOTAL_1="9" TOTAL_2="6" VAR="0.7542857142857142" WEIGHT="4.202406003873469"/>
<DICH_DATA CI_END="0.3426193597912862" CI_START="0.10021869087372785" EFFECT_SIZE="0.1853020877008067" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="73" LOG_CI_END="-0.4651881007605314" LOG_CI_START="-0.9990512746131935" LOG_EFFECT_SIZE="-0.7321196876868624" ORDER="73" O_E="-17.142045454545453" SE="0.31359387098638475" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" VAR="10.168686725206614" WEIGHT="56.653532389889605"/>
<DICH_DATA CI_END="6.00172262275839" CI_START="0.10984190233994133" EFFECT_SIZE="0.8119363461506348" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.77827592008099" LOG_CI_START="-0.959231954207345" LOG_EFFECT_SIZE="-0.09047801706317755" ORDER="74" O_E="-0.20000000000000018" SE="1.0206207261596576" STUDY_ID="STD-Williams-1981" TOTAL_1="8" TOTAL_2="7" VAR="0.96" WEIGHT="5.348516732202598"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.194826778771723" CI_END="5.168193347091096" CI_START="0.8525615256383928" DF="3" EFFECT_SIZE="2.0990957112028448" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="17" I2="63.39153857685747" ID="CMP-001.16.02" LOG_CI_END="0.7133387526658288" LOG_CI_START="-0.06927427007026263" LOG_EFFECT_SIZE="0.3220322412977831" NO="2" P_CHI2="0.042152270247856505" P_Z="0.1067477324919115" STUDIES="4" TAU2="0.0" TOTAL_1="42" TOTAL_2="41" WEIGHT="26.362875646187963" Z="1.6129851573328788">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<DICH_DATA CI_END="48.379264375248546" CI_START="1.3454827571440997" EFFECT_SIZE="8.068052182541503" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="1.6846592604665558" LOG_CI_START="0.12887813649207855" LOG_EFFECT_SIZE="0.9067686984793171" ORDER="75" O_E="2.5" SE="0.9138735334633755" STUDY_ID="STD-Sharma-1-1984" TOTAL_1="10" TOTAL_2="10" VAR="1.1973684210526314" WEIGHT="6.67098441105313"/>
<DICH_DATA CI_END="27.860894352573347" CI_START="0.8516689339519903" EFFECT_SIZE="4.871165999245475" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="1.4449950534430513" LOG_CI_START="-0.06972919408275367" LOG_EFFECT_SIZE="0.6876329296801488" ORDER="76" O_E="2.0" SE="0.8897565210026093" STUDY_ID="STD-Sharma-2-1984" TOTAL_1="10" TOTAL_2="10" VAR="1.263157894736842" WEIGHT="7.03752201605605"/>
<DICH_DATA CI_END="12.631516172862822" CI_START="0.2609040974450737" EFFECT_SIZE="1.8153826942117812" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.1014554824625544" LOG_CI_START="-0.5835191003408984" LOG_EFFECT_SIZE="0.25896819106082797" ORDER="77" O_E="0.6086956521739131" SE="0.989762410697451" STUDY_ID="STD-Tribe-1976" TOTAL_1="11" TOTAL_2="12" VAR="1.0207939508506616" WEIGHT="5.687222423183292"/>
<DICH_DATA CI_END="1.6051462213458865" CI_START="0.04821247784398165" EFFECT_SIZE="0.27818712521069233" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2055146007478365" LOG_CI_START="-1.3168405477056522" LOG_EFFECT_SIZE="-0.5556629734789079" ORDER="78" O_E="-1.5999999999999996" SE="0.8942389499810995" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" VAR="1.250526315789474" WEIGHT="6.967146795895491"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.94089501575916" CI_END="2.8570742286797284" CI_START="0.5875966082722494" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.295687896969892" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="20" I2="84.16125532872682" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.455921523787444" LOG_CI_START="-0.23092071971108247" LOG_EFFECT_SIZE="0.11250040203818076" METHOD="PETO" MODIFIED="2008-08-01 09:48:45 +0100" MODIFIED_BY="Toby J Lasserson" NO="17" P_CHI2="2.812019736511129E-4" P_Q="0.8741593251274977" P_Z="0.5208346634032422" Q="0.025083447011905596" RANDOM="NO" SCALE="204.1915759763056" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="56" WEIGHT="99.99999999999999" Z="0.6420593326292222">
<NAME>Clinical Failure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="18.915811568747255" CI_END="3.1196045688469085" CI_START="0.5666613979138226" DF="2" EFFECT_SIZE="1.3295711661739424" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" I2="89.42683483216547" ID="CMP-001.17.01" LOG_CI_END="0.49409954771988485" LOG_CI_START="-0.24667637134301965" LOG_EFFECT_SIZE="0.12371158818843261" NO="1" P_CHI2="7.807045790064748E-5" P_Z="0.5127004661770844" STUDIES="3" TAU2="0.0" TOTAL_1="48" TOTAL_2="44" WEIGHT="85.96868511754369" Z="0.6546386054943799">
<NAME>Intravenous beta-agonist vs. inhaled beta-agonist</NAME>
<DICH_DATA CI_END="0.3841372282684599" CI_START="0.018908251672848472" EFFECT_SIZE="0.08522536822455204" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.4155136015875354" LOG_CI_START="-1.7233486257787953" LOG_EFFECT_SIZE="-1.0694311136831653" ORDER="79" O_E="-4.172413793103448" SE="0.7682287670977254" STUDY_ID="STD-Browne-1997" TOTAL_1="14" TOTAL_2="15" VAR="1.6944114149821643" WEIGHT="27.580876831225424"/>
<DICH_DATA CI_END="29.350685942298067" CI_START="0.47365253004458" EFFECT_SIZE="3.7285421621745627" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4676182554123853" LOG_CI_START="-0.3245401385414885" LOG_EFFECT_SIZE="0.5715390584354483" ORDER="80" O_E="1.1875" SE="1.0527227119356304" STUDY_ID="STD-Lawford-1978" TOTAL_1="9" TOTAL_2="7" VAR="0.90234375" WEIGHT="14.687950994734082"/>
<DICH_DATA CI_END="17.609144359957707" CI_START="1.609662423595449" EFFECT_SIZE="5.323981403789052" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="1.2457382538220834" LOG_CI_START="0.2067348058816501" LOG_EFFECT_SIZE="0.7262365298518667" ORDER="81" O_E="4.48936170212766" SE="0.6103157684702254" STUDY_ID="STD-Salmeron-1994" TOTAL_1="25" TOTAL_2="22" VAR="2.6846694353140315" WEIGHT="43.69985729158419"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.133078482708214" CI_START="0.13396878753340088" DF="0" EFFECT_SIZE="1.1061407915703194" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="0.9606171896593676" LOG_CI_START="-0.8729963731350275" LOG_EFFECT_SIZE="0.043810408262170156" NO="2" P_CHI2="1.0" P_Z="0.925380373047717" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="12" WEIGHT="14.031314882456302" Z="0.09365858115816934">
<NAME>Intravenous beta-agonist vs. intravenous methylxanthine</NAME>
<DICH_DATA CI_END="9.133078482708214" CI_START="0.13396878753340088" EFFECT_SIZE="1.1061407915703194" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9606171896593676" LOG_CI_START="-0.8729963731350275" LOG_EFFECT_SIZE="0.043810408262170156" ORDER="82" O_E="0.08695652173913038" SE="1.077073683318948" STUDY_ID="STD-Tribe-1976" TOTAL_1="11" TOTAL_2="12" VAR="0.8620037807183364" WEIGHT="14.031314882456302"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-08-01 09:49:05 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>% Predicted PEFR Trials</NAME>
<CONT_OUTCOME CHI2="2.961955963230169" CI_END="4.162026013531493" CI_START="-7.000523963381445" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4192489749249761" ESTIMABLE="YES" I2="32.4770514880007" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2008-08-01 09:48:52 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.22741523131574304" P_Q="1.0" P_Z="0.6182059994572535" Q="0.0" RANDOM="YES" SCALE="46.086947862041846" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="9.307921288826787" TOTALS="YES" TOTAL_1="55" TOTAL_2="54" UNITS="" WEIGHT="100.0" Z="0.498394521270064">
<NAME>% pred PEFR at 1 hour</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.745919735271073" CI_START="-2.7459197352710736" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-31.0" MEAN_2="-32.0" ORDER="83" SD_1="6.9" SD_2="9.1" SE="1.9112186574949388" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="35" WEIGHT="62.56665497881554"/>
<CONT_DATA CI_END="2.582463545494159" CI_START="-24.582463545494157" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="-42.0" MEAN_2="-31.0" ORDER="84" SD_1="15.1" SD_2="10.4" SE="6.929955679099666" STUDY_ID="STD-Hussein-1986" TOTAL_1="7" TOTAL_2="7" WEIGHT="14.143991901890532"/>
<CONT_DATA CI_END="7.799435121843622" CI_START="-11.999435121843625" EFFECT_SIZE="-2.1000000000000014" ESTIMABLE="YES" MEAN_1="-21.3" MEAN_2="-19.2" ORDER="85" SD_1="12.1" SD_2="12.1" SE="5.050825015117168" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="23.28935311929393"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8918655048864609" CI_END="0.8647072925165942" CI_START="-6.142263272552789" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.6387779900180974" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2008-08-01 09:48:56 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.34497238672246355" P_Q="1.0" P_Z="0.1398852420151699" Q="0.0" RANDOM="YES" SCALE="28.49253999767108" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="47" UNITS="" WEIGHT="100.0" Z="1.4762185100120377">
<NAME>% pred PEFR at 2 hours</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7459197352710736" CI_START="-5.745919735271073" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-34.0" MEAN_2="-32.0" ORDER="86" SD_1="6.9" SD_2="9.1" SE="1.9112186574949388" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="35" WEIGHT="87.47494137219417"/>
<CONT_DATA CI_END="2.7994351218436258" CI_START="-16.99943512184362" EFFECT_SIZE="-7.099999999999998" ESTIMABLE="YES" MEAN_1="-28.2" MEAN_2="-21.1" ORDER="87" SD_1="12.1" SD_2="12.1" SE="5.050825015117168" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="12.525058627805835"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8549932697870148" CI_END="3.3328001058474674" CI_START="-17.03159118984864" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.849395542000587" ESTIMABLE="YES" I2="46.09144861669406" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2008-08-01 09:49:00 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="0.17320394971730613" P_Q="1.0" P_Z="0.18735789141674136" Q="0.0" RANDOM="YES" SCALE="46.086947862041846" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="32.63505019305031" TOTALS="YES" TOTAL_1="44" TOTAL_2="42" UNITS="" WEIGHT="100.0" Z="1.3184355361534972">
<NAME>% pred PEFR at 3 hours</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.05408026472892358" CI_START="-7.54591973527107" EFFECT_SIZE="-3.799999999999997" ESTIMABLE="YES" MEAN_1="-36.9" MEAN_2="-33.1" ORDER="88" SD_1="6.9" SD_2="9.1" SE="1.9112186574949388" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="35" WEIGHT="74.37482737814632"/>
<CONT_DATA CI_END="1.0100169383404705" CI_START="-32.410016938340476" EFFECT_SIZE="-15.700000000000003" ESTIMABLE="YES" MEAN_1="-46.7" MEAN_2="-31.0" ORDER="89" SD_1="21.6" SD_2="6.5" SE="8.525675507380214" STUDY_ID="STD-Hussein-1986" TOTAL_1="7" TOTAL_2="7" WEIGHT="25.625172621853686"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5417571011832296" CI_END="0.3893627024347488" CI_START="-17.89526537850984" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.752951338037546" ESTIMABLE="YES" I2="35.13893989964147" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2008-08-01 09:49:05 +0100" MODIFIED_BY="Toby J Lasserson" NO="4" P_CHI2="0.2143569153283289" P_Q="1.0" P_Z="0.06058789891776858" Q="0.0" RANDOM="YES" SCALE="57.45342863799044" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="23.641478764478816" TOTALS="YES" TOTAL_1="44" TOTAL_2="42" UNITS="" WEIGHT="99.99999999999999" Z="1.8764909305280233">
<NAME>% pred PEFR at 6 hours</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.654080264728925" CI_START="-10.145919735271072" EFFECT_SIZE="-6.399999999999999" ESTIMABLE="YES" MEAN_1="-40.4" MEAN_2="-34.0" ORDER="90" SD_1="6.9" SD_2="9.1" SE="1.9112186574949388" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="35" WEIGHT="79.71593674105561"/>
<CONT_DATA CI_END="-0.07685156058264653" CI_START="-35.92314843941735" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="-54.0" MEAN_2="-36.0" ORDER="91" SD_1="21.6" SD_2="10.9" SE="9.144631524248844" STUDY_ID="STD-Hussein-1986" TOTAL_1="7" TOTAL_2="7" WEIGHT="20.28406325894437"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-08-01 09:50:43 +0100" MODIFIED_BY="Toby J Lasserson" NO="3">
<NAME>FEV1 Trials</NAME>
<CONT_OUTCOME CHI2="0.22461283839697405" CI_END="0.08627722773418393" CI_START="-0.11114541546322994" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.012434093864523005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.6355474415488191" P_Q="1.0" P_Z="0.8049969784115745" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="29" UNITS="" WEIGHT="100.00000000000001" Z="0.2468853193347863">
<NAME>FEV1 (L) at 15 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.09256065803972331" CI_START="-0.15256065803972335" EFFECT_SIZE="-0.030000000000000027" ESTIMABLE="YES" MEAN_1="-0.85" MEAN_2="-0.82" ORDER="92" SD_1="0.21" SD_2="0.18" SE="0.06253209702140762" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="64.868187729046"/>
<CONT_DATA CI_END="0.18653928270955053" CI_START="-0.1465392827095505" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="-0.85" MEAN_2="-0.87" ORDER="93" SD_1="0.19" SD_2="0.19" SE="0.084970583144992" STUDY_ID="STD-Sharma-1-1984" TOTAL_1="10" TOTAL_2="10" WEIGHT="35.131812270954015"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.250736221584176" CI_END="0.1669621617595787" CI_START="-0.1565896693897952" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.005186246184891756" ESTIMABLE="YES" I2="29.423990489770922" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2008-08-01 09:50:43 +0100" MODIFIED_BY="Toby J Lasserson" NO="2" P_CHI2="0.23563122280540472" P_Q="1.0" P_Z="0.9498995386006758" Q="0.0" RANDOM="YES" SCALE="1.1881796426494518" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.008029894443496265" TOTALS="YES" TOTAL_1="45" TOTAL_2="42" UNITS="" WEIGHT="100.0" Z="0.06283293592397134">
<NAME>FEV1 (L) at 1 hour</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.35529339124213377" CI_START="-0.075293391242134" EFFECT_SIZE="0.1399999999999999" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.94" ORDER="94" SD_1="0.27" SD_2="0.4" SE="0.10984558539868114" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="33.90182458883515"/>
<CONT_DATA CI_END="0.06680379316967477" CI_START="-0.766803793169675" EFFECT_SIZE="-0.3500000000000001" ESTIMABLE="YES" MEAN_1="-1.08" MEAN_2="-0.73" ORDER="95" SD_1="0.51" SD_2="0.22" SE="0.21265890417240826" STUDY_ID="STD-Lawford-1978" TOTAL_1="7" TOTAL_2="6" WEIGHT="12.79327486974391"/>
<CONT_DATA CI_END="0.2817219875787403" CI_START="-0.26172198757874027" EFFECT_SIZE="0.010000000000000009" ESTIMABLE="YES" MEAN_1="-0.92" MEAN_2="-0.93" ORDER="96" SD_1="0.31" SD_2="0.31" SE="0.13863621460498696" STUDY_ID="STD-Sharma-1-1984" TOTAL_1="10" TOTAL_2="10" WEIGHT="25.001538046262706"/>
<CONT_DATA CI_END="0.24823600732502576" CI_START="-0.24823600732502576" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.92" MEAN_2="-0.92" ORDER="97" SD_1="0.25" SD_2="0.24" SE="0.1266533514304751" STUDY_ID="STD-Williams-1981" TOTAL_1="8" TOTAL_2="7" WEIGHT="28.303362495158233"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.06449641875148523" CI_END="0.23772489524837045" CI_START="-0.1481400485122286" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.044792423368070926" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.7995253429233635" P_Q="1.0" P_Z="0.649082161731489" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="0.45503763947085873">
<NAME>FEV1 (L) at 3 hours</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3439875576150769" CI_START="-0.20398755761507675" EFFECT_SIZE="0.07000000000000006" ESTIMABLE="YES" MEAN_1="-0.97" MEAN_2="-1.04" ORDER="98" SD_1="0.41" SD_2="0.46" SE="0.13979213892513112" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="49.58484673614176"/>
<CONT_DATA CI_END="0.2917219875787403" CI_START="-0.25172198757874026" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="-0.89" MEAN_2="-0.91" ORDER="99" SD_1="0.31" SD_2="0.31" SE="0.13863621460498696" STUDY_ID="STD-Sharma-1-1984" TOTAL_1="10" TOTAL_2="10" WEIGHT="50.415153263858244"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-08-01 09:51:21 +0100" MODIFIED_BY="Toby J Lasserson" NO="4">
<NAME>Comparison by Quality</NAME>
<CONT_OUTCOME CHI2="18.812840034076967" CI_END="42.56933120229236" CI_START="-3.6335162387940336" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="19.467907481749165" ESTIMABLE="YES" I2="68.10688875719033" I2_Q="27.095448270034055" ID="CMP-004.01" MODIFIED="2008-08-01 09:50:50 +0100" MODIFIED_BY="Toby J Lasserson" NO="1" P_CHI2="0.004491681281048487" P_Q="0.24152766757400734" P_Z="0.098597700696974" Q="1.3716564690006456" RANDOM="YES" SCALE="142.46079019154058" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="595.529970402639" TOTALS="YES" TOTAL_1="203" TOTAL_2="193" UNITS="" WEIGHT="100.0" Z="1.6516903018689375">
<NAME>PEFR ( l/min) at 60 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.9739872783236825" CI_END="34.2244138793406" CI_START="-17.63417835522304" DF="3" EFFECT_SIZE="8.29511776205878" ESTIMABLE="YES" I2="39.68621485877522" ID="CMP-004.01.01" NO="1" P_CHI2="0.17371202460227253" P_Z="0.5306475240305699" STUDIES="4" TAU2="277.7453668160793" TOTAL_1="83" TOTAL_2="75" WEIGHT="52.21462894691998" Z="0.6270178715078075">
<NAME>Strong Methodological Quality</NAME>
<CONT_DATA CI_END="29.073522651339943" CI_START="-53.07352265133994" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="-137.0" MEAN_2="-125.0" ORDER="100" SD_1="45.9" SD_2="47.8" SE="20.95626398001323" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="13.426690305101278"/>
<CONT_DATA CI_END="32.683688388048324" CI_START="-10.483688388048332" EFFECT_SIZE="11.099999999999994" ESTIMABLE="YES" MEAN_1="-137.9" MEAN_2="-149.0" ORDER="101" SD_1="37.2" SD_2="53.4" SE="11.012288265650648" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" WEIGHT="19.381305733095413"/>
<CONT_DATA CI_END="100.47276076274335" CI_START="1.5272392372566443" EFFECT_SIZE="51.0" ESTIMABLE="YES" MEAN_1="-123.0" MEAN_2="-174.0" ORDER="102" SD_1="82.0" SD_2="90.0" SE="25.241668292365663" STUDY_ID="STD-Salmeron-1994" TOTAL_1="25" TOTAL_2="22" WEIGHT="11.270257871152952"/>
<CONT_DATA CI_END="38.35618249493628" CI_START="-92.35618249493628" EFFECT_SIZE="-27.0" ESTIMABLE="YES" MEAN_1="-161.0" MEAN_2="-134.0" ORDER="103" SD_1="85.0" SD_2="64.0" SE="33.34560380213999" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="8.136375037570337"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.795368505081873" CI_END="64.16047855350894" CI_START="1.179977269247921" DF="2" EFFECT_SIZE="32.67022791137843" ESTIMABLE="YES" I2="65.48968373199686" ID="CMP-004.01.02" NO="2" P_CHI2="0.05515086591976881" P_Z="0.04201150411597283" STUDIES="3" TAU2="501.7805974251663" TOTAL_1="120" TOTAL_2="118" WEIGHT="47.78537105308002" Z="2.0334061738888964">
<NAME>Weak Methodological Quality</NAME>
<CONT_DATA CI_END="52.82695628312137" CI_START="-18.82695628312137" EFFECT_SIZE="17.0" ESTIMABLE="YES" MEAN_1="-133.0" MEAN_2="-150.0" ORDER="104" SD_1="46.1" SD_2="65.8" SE="18.279395216299804" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="14.94356580144184"/>
<CONT_DATA CI_END="75.28063808369018" CI_START="37.1193619163098" EFFECT_SIZE="56.19999999999999" ESTIMABLE="YES" MEAN_1="-200.0" MEAN_2="-256.2" ORDER="105" SD_1="58.5" SD_2="70.0" SE="9.735198317007775" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="20.125231473760234"/>
<CONT_DATA CI_END="55.69199976487419" CI_START="-31.69199976487419" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="-99.0" MEAN_2="-111.0" ORDER="106" SD_1="40.8" SD_2="64.4" SE="22.292246239987627" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="12.716573777877942"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.422576981312071" CI_END="52.417241034970885" CI_START="-18.596027056985207" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="16.91060698899284" ESTIMABLE="YES" I2="80.54799788884064" I2_Q="0.0" ID="CMP-004.02" NO="2" P_CHI2="0.001488932644428509" P_Q="0.3436163221028664" P_Z="0.35058022783773357" Q="0.8968929092285128" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="968.4191634940717" TOTALS="YES" TOTAL_1="147" TOTAL_2="143" UNITS="" WEIGHT="100.00000000000003" Z="0.9334644509591763">
<NAME>PEFR ( l/min) at 120 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.6302109872066874" CI_END="18.882994789239795" CI_START="-21.418568804372192" DF="1" EFFECT_SIZE="-1.267787007566198" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" NO="1" P_CHI2="0.427278156606277" P_Z="0.9018606804539041" STUDIES="2" TAU2="0.0" TOTAL_1="47" TOTAL_2="44" WEIGHT="48.43319461450143" Z="0.12331118960810812">
<NAME>Strong Methodological Quality</NAME>
<CONT_DATA CI_END="76.24205361884773" CI_START="-36.242053618847734" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="-157.0" MEAN_2="-177.0" ORDER="107" SD_1="57.5" SD_2="70.2" SE="28.695452601414043" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="18.315619816490635"/>
<CONT_DATA CI_END="17.18368838804832" CI_START="-25.983688388048332" EFFECT_SIZE="-4.400000000000006" ESTIMABLE="YES" MEAN_1="-152.4" MEAN_2="-148.0" ORDER="108" SD_1="37.2" SD_2="53.4" SE="11.012288265650648" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" WEIGHT="30.117574798010793"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.6637008893289815" CI_END="82.63326854197022" CI_START="-28.189107202080297" DF="1" EFFECT_SIZE="27.222080669944962" ESTIMABLE="YES" I2="78.55780154580452" ID="CMP-004.02.02" NO="2" P_CHI2="0.030806794093356293" P_Z="0.335608002994076" STUDIES="2" TAU2="1285.1427870481245" TOTAL_1="100" TOTAL_2="99" WEIGHT="51.56680538549859" Z="0.9628795148835353">
<NAME>Weak Methodological Quality</NAME>
<CONT_DATA CI_END="71.444903854144" CI_START="31.55509614585594" EFFECT_SIZE="51.49999999999997" ESTIMABLE="YES" MEAN_1="-227.9" MEAN_2="-279.4" ORDER="109" SD_1="67.9" SD_2="67.1" SE="10.176158343452679" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="30.61532206954654"/>
<CONT_DATA CI_END="42.229043886081335" CI_START="-53.62904388608134" EFFECT_SIZE="-5.700000000000003" ESTIMABLE="YES" MEAN_1="-127.7" MEAN_2="-122.0" ORDER="110" SD_1="65.4" SD_2="50.1" SE="24.454043168211008" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="20.95148331595205"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="23.262490750870516" CI_END="45.16139783653253" CI_START="-17.373319434095546" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="13.894039201218494" ESTIMABLE="YES" I2="78.50617092749239" I2_Q="71.04761068058755" ID="CMP-004.03" MODIFIED="2008-08-01 09:50:59 +0100" MODIFIED_BY="Toby J Lasserson" NO="3" P_CHI2="3.007080667942752E-4" P_Q="0.06310104983635278" P_Z="0.3837900131536338" Q="3.4539463702551982" RANDOM="YES" SCALE="122.81820305606797" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1065.078792469858" TOTALS="YES" TOTAL_1="179" TOTAL_2="184" UNITS="" WEIGHT="100.0" Z="0.8709343424813538">
<NAME>PEFR ( l/min) Final</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.1414781436135635" CI_END="11.32558954427737" CI_START="-32.836083261369794" DF="2" EFFECT_SIZE="-10.755246858546212" ESTIMABLE="YES" I2="6.606564911039954" ID="CMP-004.03.01" NO="1" P_CHI2="0.34275531022560535" P_Z="0.3397449747793284" STUDIES="3" TAU2="43.61036477915045" TOTAL_1="59" TOTAL_2="66" WEIGHT="44.96653744603421" Z="0.9546692934554123">
<NAME>Strong Methodological Quality</NAME>
<CONT_DATA CI_END="76.24205361884773" CI_START="-36.242053618847734" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="-157.0" MEAN_2="-177.0" ORDER="111" SD_1="57.5" SD_2="70.2" SE="28.695452601414043" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="13.476199351030921"/>
<CONT_DATA CI_END="2.283688388048315" CI_START="-40.88368838804834" EFFECT_SIZE="-19.30000000000001" ESTIMABLE="YES" MEAN_1="-180.5" MEAN_2="-161.2" ORDER="112" SD_1="37.2" SD_2="53.4" SE="11.012288265650648" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" WEIGHT="21.452288800871855"/>
<CONT_DATA CI_END="89.1529309810806" CI_START="-61.1529309810806" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="-240.0" MEAN_2="-254.0" ORDER="113" SD_1="115.0" SD_2="90.0" SE="38.34403671387705" STUDY_ID="STD-Salmeron-1994" TOTAL_1="12" TOTAL_2="22" WEIGHT="10.038049294131437"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.869819665730466" CI_END="60.6884202755715" CI_START="-6.198466108347834" DF="2" EFFECT_SIZE="27.244977083611833" ESTIMABLE="YES" I2="65.92740298860423" ID="CMP-004.03.02" NO="2" P_CHI2="0.053135602975157625" P_Z="0.11033240828534785" STUDIES="3" TAU2="567.6364695178492" TOTAL_1="120" TOTAL_2="118" WEIGHT="55.0334625539658" Z="1.5967008401914884">
<NAME>Weak Methodological Quality</NAME>
<CONT_DATA CI_END="56.79831728522501" CI_START="-16.79831728522501" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="-148.0" MEAN_2="-168.0" ORDER="114" SD_1="46.1" SD_2="68.4" SE="18.774996671104898" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="17.95307509251041"/>
<CONT_DATA CI_END="71.444903854144" CI_START="31.55509614585594" EFFECT_SIZE="51.49999999999997" ESTIMABLE="YES" MEAN_1="-227.9" MEAN_2="-279.4" ORDER="115" SD_1="67.9" SD_2="67.1" SE="10.176158343452679" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="21.77750215944591"/>
<CONT_DATA CI_END="42.229043886081335" CI_START="-53.62904388608134" EFFECT_SIZE="-5.700000000000003" ESTIMABLE="YES" MEAN_1="-127.7" MEAN_2="-122.0" ORDER="116" SD_1="65.4" SD_2="50.1" SE="24.454043168211008" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="15.302885302009477"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="28.785195603175325" CI_END="9.515216302331545" CI_START="-3.9035800288996643" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="2.8058181367159407" ESTIMABLE="YES" I2="75.68194395306516" I2_Q="0.0" ID="CMP-004.04" NO="4" P_CHI2="1.5833387459307513E-4" P_Q="0.4367027283196314" P_Z="0.4124204039366516" Q="0.6049316119470516" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="66.67091831501915" TOTALS="YES" TOTAL_1="214" TOTAL_2="205" UNITS="" WEIGHT="100.0" Z="0.8196416965258388">
<NAME>Heart Rate at 60 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.117350236460736" CI_END="10.855162036791244" CI_START="-1.08004841175363" DF="4" EFFECT_SIZE="4.887556812518807" ESTIMABLE="YES" I2="43.79930919362638" ID="CMP-004.04.01" NO="1" P_CHI2="0.12981528431744827" P_Z="0.10844111884274805" STUDIES="5" TAU2="19.943892491238646" TOTAL_1="94" TOTAL_2="87" WEIGHT="62.05621949683382" Z="1.6052394494808695">
<NAME>Strong Methodological Quality</NAME>
<CONT_DATA CI_END="24.994746747057242" CI_START="-2.9947467470572438" EFFECT_SIZE="11.0" ESTIMABLE="YES" MEAN_1="129.0" MEAN_2="118.0" ORDER="117" SD_1="12.2" SD_2="19.0" SE="7.1403081166011315" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="9.960034953549375"/>
<CONT_DATA CI_END="15.44488594622647" CI_START="0.5551140537735293" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="114.0" MEAN_2="106.0" ORDER="118" SD_1="17.0" SD_2="15.0" SE="3.7984809950339806" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" WEIGHT="14.449520501938666"/>
<CONT_DATA CI_END="17.62168316833518" CI_START="-3.621683168335183" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="122.0" MEAN_2="115.0" ORDER="119" SD_1="18.0" SD_2="19.0" SE="5.4193256876747045" STUDY_ID="STD-Salmeron-1994" TOTAL_1="25" TOTAL_2="22" WEIGHT="12.201655417796486"/>
<CONT_DATA CI_END="3.223334816036017" CI_START="-14.423334816036006" EFFECT_SIZE="-5.599999999999994" ESTIMABLE="YES" MEAN_1="101.0" MEAN_2="106.6" ORDER="120" SD_1="9.3" SD_2="12.2" SE="4.501784158093389" STUDY_ID="STD-Tribe-1976" TOTAL_1="11" TOTAL_2="12" WEIGHT="13.479271000874949"/>
<CONT_DATA CI_END="17.958744974431582" CI_START="-3.9587449744315837" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="126.0" MEAN_2="119.0" ORDER="121" SD_1="14.0" SD_2="11.0" SE="5.5912991569604165" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" WEIGHT="11.965737622674347"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.675618844251046" CI_END="12.034936297094015" CI_START="-13.414315782334105" DF="2" EFFECT_SIZE="-0.6896897426200452" ESTIMABLE="YES" I2="81.26572305382535" ID="CMP-004.04.02" NO="2" P_CHI2="0.004806400734937766" P_Z="0.9153979965434335" STUDIES="3" TAU2="99.33151668099913" TOTAL_1="120" TOTAL_2="118" WEIGHT="37.94378050316619" Z="0.1062323601356197">
<NAME>Weak Methodological Quality</NAME>
<CONT_DATA CI_END="17.381014612156548" CI_START="-2.581014612156535" EFFECT_SIZE="7.400000000000006" ESTIMABLE="YES" MEAN_1="115.4" MEAN_2="108.0" ORDER="122" SD_1="16.5" SD_2="15.3" SE="5.092447968883873" STUDY_ID="STD-Johnson-1978" TOTAL_1="20" TOTAL_2="19" WEIGHT="12.654397213277267"/>
<CONT_DATA CI_END="-4.945932567930403" CI_START="-15.054067432069598" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="95.0" MEAN_2="105.0" ORDER="123" SD_1="14.1" SD_2="19.6" SE="2.578653216046537" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="15.982558289174861"/>
<CONT_DATA CI_END="18.085579670297577" CI_START="-12.085579670297575" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="117.0" MEAN_2="114.0" ORDER="124" SD_1="19.9" SD_2="16.7" SE="7.696865753294806" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="9.306825000714058"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="45.21345438966597" CI_END="14.758901121077256" CI_START="-6.85305279321174" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="3.9529241639327584" ESTIMABLE="YES" I2="88.94134485521016" I2_Q="60.72143413596073" ID="CMP-004.05" NO="5" P_CHI2="1.3128974574172503E-8" P_Q="0.11057997002099162" P_Z="0.47339103157715223" Q="2.5459178002105487" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="155.58370584676211" TOTALS="YES" TOTAL_1="173" TOTAL_2="177" UNITS="" WEIGHT="100.0" Z="0.716972563022532">
<NAME>Heart Rate at 120 minutes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.029319965338913" CI_END="16.454986356828538" CI_START="1.3848417030774103" DF="3" EFFECT_SIZE="8.919914029952974" ESTIMABLE="YES" I2="50.24314487792542" ID="CMP-004.05.01" NO="1" P_CHI2="0.11019248169989937" P_Z="0.020331241570922132" STUDIES="4" TAU2="29.34215916532609" TOTAL_1="73" TOTAL_2="78" WEIGHT="64.9398036866698" Z="2.3201781596103954">
<NAME>Strong Methodological Quality</NAME>
<CONT_DATA CI_END="8.195230996385067" CI_START="-18.195230996385067" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="118.0" MEAN_2="123.0" ORDER="125" SD_1="18.9" SD_2="9.8" SE="6.73238442158497" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="10" TOTAL_2="10" WEIGHT="15.129798218758234"/>
<CONT_DATA CI_END="22.174148172818796" CI_START="-2.1741481728187946" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="152.0" MEAN_2="142.0" ORDER="126" SD_1="18.9" SD_2="14.0" SE="6.211414224366836" STUDY_ID="STD-Browne-1997" TOTAL_1="14" TOTAL_2="15" WEIGHT="15.655253769016573"/>
<CONT_DATA CI_END="19.2214810355241" CI_START="4.778518964475898" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="113.0" MEAN_2="101.0" ORDER="127" SD_1="17.0" SD_2="14.0" SE="3.6844968032505814" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" WEIGHT="17.96950904722865"/>
<CONT_DATA CI_END="26.125913712850213" CI_START="3.8740862871497885" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="126.0" MEAN_2="111.0" ORDER="128" SD_1="15.0" SD_2="16.0" SE="5.676590896878717" STUDY_ID="STD-Salmeron-1994" TOTAL_1="12" TOTAL_2="19" WEIGHT="16.185242651666346"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.932795871025393" CI_END="10.139856856636895" CI_START="-19.026204611598367" DF="1" EFFECT_SIZE="-4.443173877480735" ESTIMABLE="YES" I2="83.14454058863203" ID="CMP-004.05.02" NO="2" P_CHI2="0.014861689280875723" P_Z="0.5503979036233101" STUDIES="2" TAU2="93.537608162211" TOTAL_1="100" TOTAL_2="99" WEIGHT="35.06019631333019" Z="0.5971639870810671">
<NAME>Weak Methodological Quality</NAME>
<CONT_DATA CI_END="-6.6993264224911275" CI_START="-15.300673577508872" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="105.0" ORDER="129" SD_1="15.1" SD_2="14.0" SE="2.1942615330853203" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" WEIGHT="18.950977586543903"/>
<CONT_DATA CI_END="15.277885508958784" CI_START="-7.277885508958784" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="114.0" MEAN_2="110.0" ORDER="130" SD_1="14.3" SD_2="13.2" SE="5.754128952326321" STUDY_ID="STD-Van-Renterghem-1987" TOTAL_1="11" TOTAL_2="12" WEIGHT="16.109218726786285"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="28.752506296716035" CI_END="0.6783657833638898" CI_START="0.2511985827599571" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.41280082772913285" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="85" I2="79.1322539395973" I2_Q="94.35036320538357" ID="CMP-004.06" LOG_CI_END="-0.16853606592677867" LOG_CI_START="-0.5999828151787366" LOG_EFFECT_SIZE="-0.3842594405527576" METHOD="PETO" NO="6" P_CHI2="6.776077867443053E-5" P_Q="2.585942332611335E-5" P_Z="4.808459815742316E-4" Q="17.700252889759334" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="185" TOTAL_2="175" WEIGHT="100.00000000000001" Z="3.491205649404935">
<NAME>Autonomic Side Effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.137518375731972" CI_END="5.6588570174774615" CI_START="0.8807730602599944" DF="4" EFFECT_SIZE="2.232525209904105" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" I2="56.224438238904504" ID="CMP-004.06.01" LOG_CI_END="0.7527287207412942" LOG_CI_START="-0.05513597736890459" LOG_EFFECT_SIZE="0.34879637168619476" NO="1" P_CHI2="0.057752684292728285" P_Z="0.09056349705677509" STUDIES="5" TAU2="0.0" TOTAL_1="88" TOTAL_2="81" WEIGHT="28.521813816126297" Z="1.6924327255352756">
<NAME>Strong Methodological Quality</NAME>
<DICH_DATA CI_END="67.1320691203735" CI_START="1.1350440642063548" EFFECT_SIZE="8.729138363720136" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.8269300330587799" LOG_CI_START="0.05501272185531184" LOG_EFFECT_SIZE="0.9409713774570457" ORDER="131" O_E="2.0" SE="1.0408329997330665" STUDY_ID="STD-Bloomfield-1979" TOTAL_1="20" TOTAL_2="20" VAR="0.923076923076923" WEIGHT="5.928809553088089"/>
<DICH_DATA CI_END="114.55394450877218" CI_START="0.4284474579307903" EFFECT_SIZE="7.005736672237135" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.059010048120785" LOG_CI_START="-0.36810242958638467" LOG_EFFECT_SIZE="0.8454538092672002" ORDER="132" O_E="0.9577464788732395" SE="1.4256978838057217" STUDY_ID="STD-Cheong-1988" TOTAL_1="37" TOTAL_2="34" VAR="0.4919772154051067" WEIGHT="3.159909149145096"/>
<DICH_DATA CI_END="79.67413201437259" CI_START="0.873261065503689" EFFECT_SIZE="8.341241958842375" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.901317340882241" LOG_CI_START="-0.05885590250480874" LOG_EFFECT_SIZE="0.9212307191887161" ORDER="133" O_E="1.6" SE="1.151415466179596" STUDY_ID="STD-Lawford-1978" TOTAL_1="9" TOTAL_2="6" VAR="0.7542857142857142" WEIGHT="4.844684377666267"/>
<DICH_DATA CI_END="12.631516172862822" CI_START="0.2609040974450737" EFFECT_SIZE="1.8153826942117812" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.1014554824625544" LOG_CI_START="-0.5835191003408984" LOG_EFFECT_SIZE="0.25896819106082797" ORDER="134" O_E="0.6086956521739131" SE="0.989762410697451" STUDY_ID="STD-Tribe-1976" TOTAL_1="11" TOTAL_2="12" VAR="1.0207939508506616" WEIGHT="6.556434004832765"/>
<DICH_DATA CI_END="1.6051462213458865" CI_START="0.04821247784398165" EFFECT_SIZE="0.27818712521069233" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2055146007478365" LOG_CI_START="-1.3168405477056522" LOG_EFFECT_SIZE="-0.5556629734789079" ORDER="135" O_E="-1.5999999999999996" SE="0.8942389499810995" STUDY_ID="STD-Williams-1975" TOTAL_1="11" TOTAL_2="9" VAR="1.250526315789474" WEIGHT="8.031976731394076"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9147350312247253" CI_END="0.3787820030006993" CI_START="0.11696929229726998" DF="1" EFFECT_SIZE="0.21048957890103298" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="76" I2="47.773452530381284" ID="CMP-004.06.02" LOG_CI_END="-0.4216106637320276" LOG_CI_START="-0.931928137709008" LOG_EFFECT_SIZE="-0.6767694007205178" NO="2" P_CHI2="0.16643847718406657" P_Z="2.0089907213747226E-7" STUDIES="2" TAU2="0.0" TOTAL_1="97" TOTAL_2="94" WEIGHT="71.47818618387372" Z="5.198503750670333">
<NAME>Weak Methodological Quality</NAME>
<DICH_DATA CI_END="0.3426193597912862" CI_START="0.10021869087372785" EFFECT_SIZE="0.1853020877008067" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="73" LOG_CI_END="-0.4651881007605314" LOG_CI_START="-0.9990512746131935" LOG_EFFECT_SIZE="-0.7321196876868624" ORDER="136" O_E="-17.142045454545453" SE="0.31359387098638475" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" VAR="10.168686725206614" WEIGHT="65.3122242486621"/>
<DICH_DATA CI_END="6.00172262275839" CI_START="0.10984190233994133" EFFECT_SIZE="0.8119363461506348" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.77827592008099" LOG_CI_START="-0.959231954207345" LOG_EFFECT_SIZE="-0.09047801706317755" ORDER="137" O_E="-0.20000000000000018" SE="1.0206207261596576" STUDY_ID="STD-Williams-1981" TOTAL_1="8" TOTAL_2="7" VAR="0.96" WEIGHT="6.165961935211613"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="31.43878055395054" CI_END="6.458747072533381" CI_START="2.390472532433476" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.9293075052515514" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="27" I2="87.27686020411703" I2_Q="91.99864651549119" ID="CMP-004.07" LOG_CI_END="0.8101482777071323" LOG_CI_START="0.3784837578284586" LOG_EFFECT_SIZE="0.5943160177677954" METHOD="PETO" MODIFIED="2008-08-01 09:51:21 +0100" MODIFIED_BY="Toby J Lasserson" NO="7" P_CHI2="2.491027934259371E-6" P_Q="4.074191583016695E-4" P_Z="6.77796370508476E-8" Q="12.497885538191394" RANDOM="NO" SCALE="226.77859183662395" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="148" TOTAL_2="143" WEIGHT="100.0" Z="5.396959613857274">
<NAME>Clinical Failure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="18.940895015759157" CI_END="2.8570742286797284" CI_START="0.5875966082722494" DF="3" EFFECT_SIZE="1.2956878969698922" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="20" I2="84.16125532872682" ID="CMP-004.07.01" LOG_CI_END="0.455921523787444" LOG_CI_START="-0.23092071971108247" LOG_EFFECT_SIZE="0.11250040203818083" NO="1" P_CHI2="2.8120197365089084E-4" P_Z="0.5208346634032421" STUDIES="4" TAU2="0.0" TOTAL_1="59" TOTAL_2="56" WEIGHT="39.49832795243953" Z="0.6420593326292224">
<NAME>Strong Methodological Quality</NAME>
<DICH_DATA CI_END="0.3841372282684599" CI_START="0.018908251672848472" EFFECT_SIZE="0.08522536822455204" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.4155136015875354" LOG_CI_START="-1.7233486257787953" LOG_EFFECT_SIZE="-1.0694311136831653" ORDER="138" O_E="-4.172413793103448" SE="0.7682287670977254" STUDY_ID="STD-Browne-1997" TOTAL_1="14" TOTAL_2="15" VAR="1.6944114149821643" WEIGHT="10.89398518295583"/>
<DICH_DATA CI_END="29.350685942298067" CI_START="0.47365253004458" EFFECT_SIZE="3.7285421621745627" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4676182554123853" LOG_CI_START="-0.3245401385414885" LOG_EFFECT_SIZE="0.5715390584354483" ORDER="139" O_E="1.1875" SE="1.0527227119356304" STUDY_ID="STD-Lawford-1978" TOTAL_1="9" TOTAL_2="7" VAR="0.90234375" WEIGHT="5.801495053393673"/>
<DICH_DATA CI_END="17.609144359957707" CI_START="1.609662423595449" EFFECT_SIZE="5.323981403789052" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="1.2457382538220834" LOG_CI_START="0.2067348058816501" LOG_EFFECT_SIZE="0.7262365298518667" ORDER="140" O_E="4.48936170212766" SE="0.6103157684702254" STUDY_ID="STD-Salmeron-1994" TOTAL_1="25" TOTAL_2="22" VAR="2.6846694353140315" WEIGHT="17.260712947777982"/>
<DICH_DATA CI_END="9.133078482708214" CI_START="0.13396878753340088" EFFECT_SIZE="1.1061407915703194" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9606171896593676" LOG_CI_START="-0.8729963731350275" LOG_EFFECT_SIZE="0.043810408262170156" ORDER="141" O_E="0.08695652173913038" SE="1.077073683318948" STUDY_ID="STD-Tribe-1976" TOTAL_1="11" TOTAL_2="12" VAR="0.8620037807183364" WEIGHT="5.542134768312046"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.358488213001625" CI_START="4.279442659814606" DF="0" EFFECT_SIZE="8.107143124984223" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="7" I2="0.0" ID="CMP-004.07.02" LOG_CI_END="1.1863484687512305" LOG_CI_START="0.6313872116467589" LOG_EFFECT_SIZE="0.9088678401989947" NO="2" P_CHI2="1.0" P_Z="1.3652427602769517E-10" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="87" WEIGHT="60.50167204756047" Z="6.419721055091223">
<NAME>Weak Methodological Quality</NAME>
<DICH_DATA CI_END="15.358488213001625" CI_START="4.279442659814606" EFFECT_SIZE="8.107143124984223" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="7" LOG_CI_END="1.1863484687512305" LOG_CI_START="0.6313872116467589" LOG_EFFECT_SIZE="0.9088678401989947" ORDER="142" O_E="19.693181818181817" SE="0.325986989525694" STUDY_ID="STD-Swedish-Society-1990" TOTAL_1="89" TOTAL_2="87" VAR="9.410213252656435" WEIGHT="60.50167204756047"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>